Abstract: A wide diversity of animal models has been used to examine antidepressant activity. These range from relatively simple models sensitive to acute treatment, to highly sophisticated models that reputedly model some aspect of depressive illness and which yield a positive response to prolonged, chronic, drug treatment. In recent years antidepressant drug research has focused on the search for antidepressant therapy that has a more rapid onset of action. To be relevant, therefore, animal models must measure the time course of drug action.
INTRODUCTION
Animal models of depression are used for a variety of purposes: as screening tests to discover and develop novel antidepressant drug therapies; as simulations for investigating aspects of the neurobiology of depressive illness; and as experimental models within which the neuropharmacological mechanisms associated with antidepressant treatments, including electroconvulsive shock (ECS), may be investigated [1] [2] [3] [4] [5] . This diversity of objectives raises the question as to whether any single model can fulfil all these needs. The pessimistic view is that currently available animal models are only models of antidepressant activity (including ECS). If this is the case, they may prove adequate as both screening tests and as models to investigate neuropharmacological mechanisms associated with treatment, but their validity as simulations of the psychiatric condition is highly questionable. It can equally be argued that the validity of any animal model, whatever the objective, is small. It is therefore vital that the limitations of animal models used to investigate the neurobiology of depressive illness and associated therapies are fully recognized. This review attempts to address this problem.
Screening Tests
The essential requirement for any antidepressant screening test is that it accurately predicts antidepressant activity.
*Address correspondence to these authors at the Department of Pharmacy & Pharmacology, University of Bath, UK; E-mail: P.J.Mitchell@bath.ac.uk and P.H. Redfern@bath.ac.uk Ideally, it should also be cheap, robust, reliable and easy to use [6, 7] and should therefore be as simple as possible. The almost universal use by the pharmaceutical industry since the beginning of the 1970s of drug screening tests sensitive to acute or sub-acute drug treatment has resulted in the discovery of an array of antidepressant drugs all with pharmacological and therapeutic profiles qualitatively similar to that of the archetypal tricyclic antidepressant (TCA), imipramine, or monoamine oxidase inhibitor (MAOI), isoniazid. Undoubtedly, the success of, and consequent continued use of, such screening tests relying on acute treatment (e.g. pharmacological screening procedures or the forced swim test) not only restricted the development of animal models with improved face and construct validity, but has also largely been responsible for delaying the development of animal models in which antidepressants are active only following chronic administration.
The majority of models used routinely as antidepressant screening tests rely on an acute response to drug treatment. They are therefore of no value in the drive to identify antidepressant drugs with a more rapid onset and have limited or minimal validity as simulations of depression, c.f. [4] . Generally, the use of drug screening models has simply resulted in the identification of further 'me-too' compounds (novel compounds whose acute pharmacological profile is similar to those already available to the clinician), has provided no information on onset of clinical efficacy, has been of very limited use in furthering our knowledge of the mechanisms associated with the psychopathology of depressive illness or adaptive changes associated with the recovery process from depression, and has demonstrably failed to identify novel mechanisms and targets for future drug discovery.
However, the simplistic view that screening tests for antidepressant activity should necessarily rely on an acute response has changed during the last decade. The clinical requirement is now to identify rapid onset antidepressant treatments. Of necessity this approach involves the assessment of drug action associated with chronic/continuous drug treatment regimes and measuring an acute response is of little value. Appropriate screening tests to be used early during drug development should therefore have the ability to identify the time course of drug action associated with repeated treatment schedules. In fact, most pharmaceutical companies have now abandoned the high volume, random screening approach in favour of the development of a small number of compounds specifically designed to meet predetermined pharmacological criteria. In such a programme, the place of behavioural screening methods shifts from the discovery phase to the development phase, and the logistical disadvantages of using complex, chronic models are small, relative to the costs of testing an ineffective drug in the clinic.
The greatest immediate contribution of animal models of depression is likely to be in relation to the elucidation of the mechanisms of action of antidepressant drugs. Thirty years of clinical experience has given rise to two widely accepted axioms: that only rarely do antidepressants cause discernible clinical improvement within the first two weeks of treatment, and that they are devoid of mood elevating effects in normal human subjects. The belief that clinical efficacy is dependent on chronic treatment has led to a considerable literature describing the effects of chronic antidepressant administration in normal animals, and numerous changes in pre-and/or post-synaptic receptor function have been reported, in a variety of systems. These studies are an essential first step towards establishing mechanisms of antidepressant action. However, the inability to determine which of the many effects of antidepressants are responsible for their therapeutic actions constitutes a fundamental limitation of this approach. The development of animal models that mimic, chronically, some aspects of the human disease state and which can be challenged with established or putative 'therapies', provides a powerful methodology for investigating these problems.
Simulation Models
In contrast to the changing criteria for screening tests for antidepressant drugs, a simulation of depression aims to mimic aspects of the clinical situation. There is an inherent conflict here. It can be argued that to mimic the disease state will require a highly complex model; on the other hand reliable, reproducible data is more likely to be generated from a single model that perhaps mimics only one key symptom of the disease. In addition, if a model is to be used to investigate antidepressant actions, a slow onset, comparable to the clinical time course, is highly desirable. The model should also respond differently (either in direction of response or in response magnitude) to single and repeated (chronic/continuous) treatment regimes.
This review is concerned primarily to evaluate the suitability of the available animal models as research tools with particular emphasis on their ability to identify novel antidepressant therapies with rapid onset of action during chronic/continuous drug treatment. An additional advantage is that such animal models provide time-dependant behavioural markers of successful antidepressant treatment. These behavioural markers may then be used to identify concomitant changes in neurochemistry and neurotransmitter receptor-mediated function that may underpin the observed antidepressant-induced change in behaviour and so increase our understanding of the neurochemical mechanisms responsible for antidepressant action.
VALIDITY
Any assessment of the validity of animal models of depression must address the three dimensions of predictive, face, and construct validity [4, 7, 8] . The concept of predictive validity implies that manipulations known to influence the pathological state should have similar effects in the model. Face validity refers to a phenomenological similarity between the model and the disorder being modelled. Construct validity implies that the model has a sound theoretical rationale. Some reviewers have variously advocated the primacy of one or other of these approaches (predictive validity/ correlation: e.g. [9] ; face validity/isomorphism: e.g. [10] ; construct validity/correlation, e.g. [11] ). In principle, construct validity is the most important of the three dimensions. In practice, however, the construct validity of animal models of depression is difficult to determine, and thus assessment of the validity of a model is generally based on elements of all three dimensions. We therefore begin by reviewing briefly the three sets of validation criteria, as they apply to animal models of depression, with particular emphasis on those that are sensitive to chronic drug treatment.
Predictive Validity
The predictive validity of an animal model of depression is a measure of that model's ability to identify drugs with clinical efficacy against depression. A valid test should be sensitive and specific: it should respond to effective antidepressant treatments ('true positive' effects), including ECS, and should fail to respond to ineffective agents ('true negative' effects). A model with high predictive validity should therefore maximize identification of both 'true positives' and 'true negatives', and should minimize identification of 'false positives' and 'false negatives'. Furthermore, positive responses should occur at behaviourally selective doses (i.e. those which do not generally disrupt behaviour, or induce motor impairment) that are within or close to the clinical range, and should be demonstrable with a range of structurally diverse compounds. It has to be recognized that no animal model has a 100% prediction rate although some complex experimental paradigms have approached this level of predictive ability. Part of the problem lies not so much with the preclinical model but with the fact that there is a lack of consensus in the clinical literature as to whether certain drugs (e.g. anticholinergics) possess antidepressant activity. It is generally agreed that the most effective treatment for depressive illness is electroconvulsive therapy (ECT). A suitable starting point to test the validity of an animal model should therefore be to demonstrate a positive response to repeated ECS. A failure to respond appropriately to ECS would lead one to severely question the predictive validity of the model. About 30% of depressed patients fail to respond to antidepressant drug treatment while the response rate for ECT is slightly higher. The occurrence of refractory patients probably reflects the heterogeneity of depressive illness. Nevertheless, a model that did not respond to the benchmark TCAs, selective serotonin reuptake inhibitors (SSRIs), or the recently developed serotonin-noradrenaline reuptake inhibitors (SNRIs), would not be taken seriously.
Beyond the clinically established antidepressant treatments (TCAs, MAOIs, SSRIs, SNRIs, and some atypical antidepressants, such as mianserin) are a wide range of newer compounds for which antidepressant activity has been claimed, ranging from pharmacologically-selective compounds that are probably effective (e.g. α 2 -adrenoceptor antagonists; ligands for serotonin (5-hydroxytryptamine; 5-HT) 5HT 1A , 5-HT 2A and 5-HT 2C receptor subtypes, and nmethyl-d-aspartate (NMDA) receptor ligands), through preparations of mixed pharmacological activity (e.g. SSRI with selective 5-HT 1A receptor antagonist activity) to compounds of uncertain status (e.g. phosphodiesterase inhibitors; calcium antagonists; anticonvulsants). Even in the case of the SSRIs, whose antidepressant efficacy is beyond doubt, it is still uncertain whether their spectrum of activity is identical to that of the TCAs. Therefore, while a well-rounded description of an animal model of depression should include an account of its pharmacological profile broader than that provided by its response to traditional antidepressants, the contribution of these newer compounds to validation is limited.
To some extent, similar uncertainties exist in relation to drugs which are ineffective as antidepressants. The 'false positives' most commonly encountered in animal models of depression are psychomotor stimulants, anticholinergics and opiates. However, prior to the development of antidepressants, drugs from all three of these classes were regularly prescribed for the relief of depression (see [12] ). , Some of the opiates (e.g. buprenorphine) almost certainly have antidepressant activity [13] , but anticholinergics and stimulants have never been properly assessed, as their use was discontinued prior to the introduction of blind clinical trials. Again, the uncertain status of these compounds to some extent undermines their value as definitive standards of negative control.
Finally, a positive response to antidepressant drugs is insufficient to define an animal model of depression. Some antidepressants are active in animal models of anxiety and panic, following chronic treatment [14, 15] , and indeed, are increasingly seen as the drugs of choice in many forms of anxiety [16] . It is therefore crucial for establishing the predictive validity of an animal model of depression to demonstrate that the model does not respond to benzodiazepines.
Face Validity
Face validity is a measure of the model's ability to reproduce core symptoms of the disease under scrutiny. Clearly, not all symptoms of a psychiatric condition carry equal weight, and for an animal model to be valid, a resemblance to the clinically defined core symptoms of the disorder carries more weight than a resemblance to any subsidiary symptoms [17] . The most recent edition of the Diagnostic and Statistical Manual (DSM-IV) provides a framework within which to assess these similarities. However, not all of the clinical symptoms of depression can be modelled in animals; symptoms conveyed by subjective verbal report (e.g. excessive guilt, feelings of worthlessness, suicidal ideation) are in principle excluded [4, 5] .
A DSM-IV diagnosis of major depression requires the presence of a least one of two core symptoms: loss of interest or pleasure (anhedonia) and depressed mood. Of these two core symptoms, anhedonia can be modelled in animals, but depressed mood cannot. In assessing the face validity of animal models of depression, anhedonia therefore assumes a central position. The problem here, however, is that anhedonia is also a core symptom of schizophrenia. Drug-induced reversal of anhedonia in animal models, whilst highly encouraging, should thus be considered in relation to DSM-IV criteria for both depressive illness and schizophrenia.
The subsidiary symptoms of depression in DSM-IV that are amenable to modelling in animals include psychomotor changes, fatigue or loss of energy (which might be modelled as decreased persistence), and disturbances of sleep or food intake. Interestingly, psychomotor activity, sleep and appetite may be increased or decreased in depression, and diametrically opposite changes in locomotion have been cited in support of the validity of different models. This lack of precision, together with the fact that psychomotor retardation and agitation (which are considerably more complex than gross changes in locomotor activity) may even co-exist clinically [18] , suggests that simulations in which a change in locomotor activity is the major, or only, behavioural feature should not be taken too seriously. Unfortunately, it is precisely these behaviours that feature most prominently in many animal models of depression [19] .
Because the pharmacotherapy of depression typically requires chronic drug treatment, the validity of an animal model is called into question by an acute response to conventional (e.g. TCA) antidepressant treatment. There is some evidence of very early antidepressant responses in clinical studies designed explicitly to detect them (e.g. [20] ; see also [21] ) but even so, repeated treatment is required for a full response. Acute treatment refers to a single bolus dose of drug and any acute treatment effects are usually observed within minutes or hours. Multiple acute doses may be administered, over a short period, simply to increase levels of drug in the biophase without evoking secondary adaptive changes in neurotransmitter mechanisms. In contrast, chronic treatment refers to repeated bolus doses administered for extended periods (days, weeks, months). The effects of chronic treatment may be associated with drug-induced adaptation in neurotransmitter receptor-mediated systems, rather than increased drug levels in the plasma. Thus, the effect of acute treatment may be opposite to that seen chronically, orthogonal (due to side effects, e.g. sedation) or absent. Irrespective of how it responds to acute antidepressant treatment, to be valid, an animal model of depression must respond to chronic treatment. Furthermore, since tolerance does not occur to the clinical effects of antidepressants, the response in the model must be maintained until the cessation of antidepressant treatment. This criterion has not been universally applied to animal models of depression but, in general, models in which it has been investigated have met this criterion, though tolerance to antidepressant effects has been reported in some behavioural paradigms (e.g. [22, 23] ).
Construct Validity
Evaluation of the theoretical rationale of an animal model requires a comparison of the causal pathology of the disease state with the cellular and biochemical mechanisms underlying the model. In this regard any evaluation of animal models of depression is intrinsically limited by the lack of any clear understanding of the rudimentary state of the causal pathology of depression. Indeed, there is little in the extensive literature describing neurochemical abnormalities or biochemical markers reportedly associated with depression that can be usefully employed to provide a standard against which to validate animal models. Even the most basic questions of whether the level of activity in monoaminergic systems is elevated or decreased in depression were and remain controversial [12] .
Similar problems arise in relation to modelling the aetiology of depression. It is now clear that a variety of factors are implicated in the aetiology of depression: 'psychological' factors include undesirable life events, chronic mild stress, adverse childhood experiences, and personality traits such as introversion and impulsiveness; 'biological' factors include genetic influences, and a variety of physical illnesses and medications (see [12, 24, 25] ). However, for most of these factors, there is little understanding of the processes linking a specific trigger to altered mood. In certain cases, the immediate precipitant of a depression may be clearly identified: for example, seasonal affective disorder (SAD) and postpartum depression. More usually, depression is better understood as resulting from an accumulation of a number of different risk factors [24, 26, 27] . This point has been largely overlooked in the construction of animal models of depression, which in general have assumed a single causal factor. This may be counterproductive, since few of the identified aetiological factors appear sufficiently potent alone to precipitate depression in an otherwise risk-free individual.
Although assessment of the theoretical rationale of animal models is limited by this lack of knowledge of causal pathology, a number of generalizations are possible. The major group of animal models of depression are based on responses to stressors of various kinds, and are usually justified by reference to the role of stressful life events in the aetiology of depression [27] [28] [29] . However, the relevance of very acute stress (e.g. [30] ) to depression, rather than, for example, to posttraumatic stress disorder is questionable. Furthermore, the adverse consequences of life events endure for a prolonged period of six to twelve months, in part by exacerbating ongoing life difficulties [29, 31] . Thus, life events should not be viewed as acute stressors (indeed, in the case of bereavement, a diagnosis of depression is explicitly excluded during the period of acute loss); from this perspective, it may be more appropriate to use chronic stress regimes, rather than acute stressors, to model the etiological role of life events. Other factors have been identified that confer a long-lasting vulnerability to depression, in particular, an inadequate level of social support, which to a large extent arises from inadequate socialization [26, 27, 29, 31, 32] . From these starting points, a number of animal models of depression have been developed that are based on the adverse effects of social isolation. However, with the exception of some of the primate studies, these models have largely ignored both the complexity of childhood social deprivation phenomena and the mediation of their effects through later social relationships.
Although assessment of the theoretical rationale of animal models of depression is limited by the paucity of theory, construct validity can also be evaluated at the level of constructs: that is, whether the behavioural phenomena are correctly described. This approach is best exemplified by the extensive experimental analysis of whether 'learned helplessness' is an appropriate term to describe the impairment of escape learning that follow exposure to inescapable electric shock [33] . The term 'learned helplessness' implies that the animals perform poorly because they have learned that their responses are ineffective in controlling their environment [33] . However, inescapable shock has a variety of other, simpler effects, that could also explain many of the behavioural impairments, such as decreased locomotor activity [34, 35] and analgesia [36] . In addition, while inescapable shock results in 'cognitive' impairment [37] such behavioural effects arise from impairment at the level of attentional processing rather than 'helplessness' [38] . Thus, there are many reasons to question whether the learned helplessness procedure does in fact produce 'helplessness'.
Anhedonia is another construct that has been subjected to this kind of experimental attention. Here the question is whether the animals are failing to perform rewarded behaviour because they are insensitive to rewards or for some other reason. This question has been most extensively investigated in relation to the effects of chronic sequential exposure to a variety of mild stressors (chronic mild stress: CMS). CMS has been shown to cause an antidepressantreversible decrease in the consumption of dilute sucrose solutions, which is hypothesized to reflect a decrease in the reward value of the sucrose [39, 40] . Initial studies showed that, in contrast to the effect of dilute solutions of sucrose or saccharin, CMS did not decrease the intake of plain water, food pellets, or concentrated sucrose solutions; thus the effects are not simply nonspecific changes in consummatory behaviour [41] . Some studies have suggested that decreases in sucrose intake reflect loss of body weight (e.g. [42] ). Furthermore, the effects of CMS are not confined to consummatory behaviours. CMS also attenuated or abolished place preferences established using a variety of natural or drug rewards. However, drug-induced place aversions were unaffected by CMS. Thus, the effect of CMS on place conditioning cannot be explained by nonspecific motivational impairments or a failure of associative learning (reviewed in [40] ). Finally, CMS has also been shown to cause an increase in the threshold for brain stimulation reward [43] . Together, these results support the view that CMS causes a generalized decrease in sensitivity to rewards, and that under appropriate experimental conditions, decreases in sucrose intake provide a simple means of detecting this anhedonia.
These examples of successful experimental analyses of construct validity contrast sharply with a third example, the 'behavioural despair' test [44] . This term was introduced to describe the immobility seen in rats or mice forced to swim in a confined space, based on the assumption that when the animals adopted an immobile posture, they had 'despaired' of escaping. Unfortunately, this interpretation is not susceptible to experimental analysis. Consequently, although the test continues to be very widely used, the name 'behavioural despair' has been largely abandoned, and replaced instead by the theoretically neutral term 'the forced swim test'.
Heterogeneity of Depression
It has frequently been remarked (e.g. [45] ) that the approach adopted in successive editions of the DSM, which identifies psychiatric disorders by the presence of a sufficient number of symptoms from a longer list, results in very different clinical presentations receiving the same diagnosis. However, discussion of the heterogeneity of depression is several decades older than the DSM system. It has been recognized since the 1920s that there are at least two forms of depression, but only one of them has enjoyed general agreement as to its nature [12] . This is the syndrome that has been known, variously, as autonomous depression, endogenous depression, endogenomorphic depression and melancholia. Because a consensus exists as to its existence and symptom profile, melancholia has emerged as the major subtype of depression, and its definition in DSM-IV is somewhat more restrictive than that of the parent syndrome, major depressive disorder.
Little attention has been paid to the question of sub-types of depression in the development of animal models, which have tended to focus either on an undifferentiated depressive state or on melancholia. Melancholia is defined in DSM-IV (major depressive episode with melancholic features) by the presence of anhedonia, which is also the only core symptom of major depression that is amenable to modelling in animals. Anhedonia may be readily modelled as decreased sensitivity to rewards, though, as noted above, this construct is considerably more complex than a simple decrease in the performance of a rewarded behaviour. In relation to the other symptoms that can be modelled, the diagnosis of melancholia specifies the direction of changes in appetite and sleep (decreased), although, as in the diagnosis of major depressive disorder, psychomotor changes could be in either direction (retardation or agitation). In many empirical studies, psychomotor retardation has emerged as the symptom most characteristic of melancholia, while psychomotor agitation tends to be more closely associated with psychotic features such as delusions of guilt [18] . Nevertheless, there is considerable overlap between these two groups of symptoms, and agitated melancholias are not uncommon. Unlike nonmelancholic depressions, melancholia is characterized by a decrease in the latency to enter the first period of rapid eye movement (REM) sleep [46] and an increased activity of the hypothalamic-pituitary-adrenal (HPA) system, usually detected by the dexamethasone suppression test (DST) [47] . In a valid simulation of melancholia, these biological markers would be expected to coexist alongside decreased sensitivity to rewards. However, the specificity of both of these markers for melancholia is less than originally claimed.
In contrast, no consensus exists that non-melancholic depression is a homogeneous entity, and this issue has been extensively debated. Within the 'non-melancholic' spectrum, two syndromes have been described that are of interest in the present context. One of these is not recognized in DSM-IV, but has features which suggest that it might represent a coherent biological entity. This is a form of depression in which central 5-HT activity is decreased, as indicated by low concentrations of the 5-HT metabolite 5-hydroxyindole acetic acid (5-HIAA) in cerebrospinal fluid. These depressions are characterized by high levels of anxiety and agitation, and Van Praag [48] has suggested that these symptoms are primary, with depressed mood as a secondary response to a failure to cope with the consequences. It has been suggested that some animal models of depression, which are characterized by high levels of locomotor activity and/or aggression, may represent models of this subtype. There is as yet little further evidence by which to judge the validity of these claims.
A second 'non-melancholic' subtype of depression is delusional depression (previously known as psychotic depression). Delusional depression (DSM-IV major depressive episode with psychotic features) is difficult to translate into behavioural terms, being differentiated from nondelusional depression only by a greater association with psychomotor agitation [18] . Delusional depressions are pharmacologically distinct in that they respond to ECT or combinations of TCAs with neuroleptics, but not to TCAs alone [49] . The development of an animal model that responds to ECT but not to TCAs has not yet been achieved. Bipolar disorder is another well-defined diagnostic category for which there are no animal models. There are a number of animal models of mania (see [50] ), but the alternation of depressive-like and manic-like behaviours in an animal model has not yet been systematically addressed. Indeed, the episodic nature of unipolar depression (e.g. briefrecurrent depression) also remains to be explored in animal models. Table 1 lists animal models used in antidepressant drug research and measures them against the criterion that is central to current efforts in drug development, sensitivity to chronic drug treatment. The importance of this feature is that only when a model allows detection of a gradual onset of action is it possible to detect a more rapid onset. Some of the models (e.g. induction and maintenance) have the potential to demonstrate a gradual onset of action, since they have an extended time course, but this has not yet been fully investigated. The three models for which the clearest evidence for gradual onset of action exists are CMS, social hierarchy, and the resident-intruder test [8] .
ANIMAL MODELS OF CHRONIC ANTIDEPRES-SANT TREATMENT

Pharmacological Screening Tests
Pharmacological screening tests are those older models, now little used, based primarily on mechanistic interactions between antidepressants and a range of other pharmacological agents. Generally, the predictive validity of these tests for antidepressant activity is poor, and their face and construct validity as simulations of depression is minimal or zero (for an extended discussion see [4, 5, 7, 8, 12, 19] ).
However, it should be recognized that behavioural models employing acute pharmacological challenge with selective pharmacological ligands are extremely useful to elucidate whether changes in neurotransmitter receptormediated function are associated with chronic antidepressant treatment (including ECS). A prerequisite of such studies is that they should employ realistic chronic treatment schedules previously determined in a suitable animal model of antidepressant activity to reveal not only drug potency but also the time to onset of antidepressant activity (i.e. drug latency). There is no value in employing dosing schedules to examine which adaptive mechanisms may underpin the mode of action of antidepressant activity if the doses or duration of treatment either fail to induce behavioural markers highly specific for antidepressant activity or exceed those treatment schedules determined in previous behavioural experiments. Clearly, the use of very high doses or long duration of treatment risks inducing adaptive mechanisms unrelated to behavioural markers specific to antidepressant efficacy.
Models of Predisposition to Depression (i.e. Diathesis)
The Diathesis Concept [8] It is widely assumed that individuals vary in their susceptibility to psychiatric disorders, and that such disorders are typically precipitated by external or internal (e.g. hormonal) events. The term diathesis refers to a predisposition to contract the disorder and a predisposition to become depressed (a depressive diathesis) may arise in a variety of ways [8] .
Depressive diatheses have been modelled by brain lesioning, genomically, genetically and developmentally. 
Social defeat
Agonistic behaviour
Resident-intruder Social hierarchy
Animal models of depression are classified according to type and sensitivity to drug treatment. The diathesis/stress distinction is according to the evaluation of Willner and Mitchell [8] . DIATHESIS models refer to those animal models which show a predisposition to model some aspect of depressive illness. In contrast, STRESS models are those where stress is the precipitating stimulus that evokes changes in animal behaviour. S OCIAL DOMINANCE models are those that employ realistic inducing conditions to modify aspects of social behaviour and are of ecological and ethological relevance. These latter models may be considered to be a sub-set of the STRESS models that employ social stress as the precipitant. Pharmacological tests involve pharmacological interaction between different drugs and are primarily of historical interest.
However, these models have limited validity with respect to depressive illness [8] and only those sensitive to chronic drug treatment will be discussed here.
Lesion Model
Olfactory Bulbectomy
Destruction of the olfactory bulb in rats, with consequent disruption of the limbic-hypothalamic axis, has been widely used as a model of depression. Bulbectomized (OB) animals display a variety of behavioural changes, including irritability, hyperactivity, and an impairment of passive avoidance learning [51] . Recent observations suggest that OB rats exhibit increased reactivity and a reduced rate of habituation to novel stimuli [52] together with changes in the immune system and noradrenaline (NA), dopamine (DA), 5-HT, gamma-aminobutyric acid (GABA), acetylcholine (ACh) and glutaminergic neurotransmitter systems [53] . They also show an elevation of circulating corticosteroid levels (as do stressed animals), which appears to be an increased corticosteroid response to stress rather than an increase in basal levels [54] . These changes are reversed by antidepressants, including agonists at the 5-HT 1A receptor [55, 56] , SNRIs [57] and selective NA reuptake inhibitors [58] in addition to the TCAs. The most consistent effect is the reversal of the learning deficit in passive avoidance behaviour [51, 59] , although attenuation of hyperactivity in the open-field is nowadays the most commonly used behavioural predictor of antidepressant activity [53] . However, while all TCA and atypical antidepressants are effective in this test, MAOIs are not [1] . While repeated administration of TCAs is necessary to normalize behaviour in this model, a limited number of studies suggest that some SSRIs act after acute treatment [60, 61] . Recent studies suggest that the OB rat model of depression is insensitive to the potential rapid onset of antidepressant action induced by concomitant treatment with 5-HT 1A receptor antagonists [62, 63] . The implication that the model involves primarily serotonergic mechanisms is supported by the observation that the effects of subchronic treatment with imipramine and mianserin were reversed by acute administration of the 5-HT 2 receptor antagonist metergoline [64] .
Although pharmacologically specific for antidepressants, the face validity of the OB model appears slight. Unlike the stress models, the bulbectomized rat resembles an agitated hyposerotonergic, rather than a retarded, depression [65] , but beyond hyperactivity, it is difficult to discern any further points of behavioural resemblance. Indeed, increased irritability and aggression together with exaggerated reactivity to auditory and tactile stimulation may reflect additional septal damage. Nevertheless, bulbectomized rats do resemble depressed humans on a surprisingly wide range of peripheral neurochemical and immunological markers, such as abnormalities of platelet 5-HT transport and neutrophil phagocytosis [66] .
Genomic Models
HPA Transgenic
The secretion of corticotropin releasing hormone (CRH) from the paraventricular nucleus of the hypothalamus is under the control of a glucocorticoid receptor-mediated inhibitory feedback system. Conditions of extreme, prolonged stress, which may lead to depressive illness, cause reduced sensitivity of the glucocorticoid receptor, thereby reducing the effectiveness of the feedback loop, resulting in hypercortisolaemia. A transgenic mouse strain expressing glucocorticoid receptor antisense has been described which exhibits dysfunction of the HPA axis in a manner similar to that seen in depressive illness [67, 68] . Chronic treatment with antidepressants reduces plasma cortisol and adrenocorticotrophic hormone (ACTH) levels [68, 69] , by increasing glucocorticoid receptor mRNA expression [70] , with a subsequent elevation of glucocorticoid receptor activity resulting in increased sensitivity of the HPA axis to glucocorticoid negative feedback [71] . However, while behavioural and neuroendocrine responses to stress are modified in transgenic mice [72, 73] , the direction of these changes is inconsistent with a model of depressive illness: relative to wild type controls, transgenic mice exhibit reduced immobility in the forced swim test and less anxiety-related behaviour on the elevated plus maze but increased aggressive behaviour [68, 74] .
Genetic Models Selective Breeding for Muscarinic Hypersensitivity (FSL)
The Flinders Sensitive Line (FSL) rat is the result of selective breeding for sensitivity to the hypothermic effect of ACh receptor agonists and is based on the hypothesis that central cholinergic systems are important in depression since increased cholinergic sensitivity has been reported in depressed patients. Although bred for cholinergic hypersensitivity, FSL animals also show a number of other pharmacological abnormalities, including serotonergic hypersensitivity and dopaminergic hyposensitivity [75] . Relative to the control Flinders Resistant Line, FSL animals have a number of characteristics reminiscent of depression, including cholinergic supersensitivity, increased REM sleep, and reduced locomotor activity, which is further pronounced following electric footshock [76] . FSL animals also show greater immobility in the forced swim test [75] . This behaviour was normalized by chronic treatment with a high dose of imipramine, and partly reversed by desmethylimipramine (desipramine, DMI) or sertraline, but was not restored by chronic amphetamine or scopolamine [77] [78] [79] . FSL rats also exhibit a greater vulnerability to the suppressive effect of chronic mild stress on responsiveness to sweet reward [80, 81] but behave normally in the elevated plus maze, a putative animal model of anxiety [78] .
While these observations are consistent with a depressive diathesis and greater behavioural responsiveness to stress, other data are not. FSL rats have markedly elevated levels of 5-HT, NA and DA in specific brain areas which are normalized during chronic treatment with DMI [82, 83] , and hypothalamic levels of CRH and circulating levels of ACTH are lower in FSL rats [84] , indicating reduced HPA axis activity, in contrast to the increased HPA axis activity observed in depression. Similarly, acute and chronic treatment with nicotine, which has no antidepressant activity, both exhibit an antidepressant-like effect on the behaviour of FSL rats in the forced swim test [85] ; this effect was blocked by prior treatment with the nicotinic receptor antagonist, mecamylamine [86] . It should be noted that the major pharmacological evidence supporting the FSL strain as a model of depression derives from studies using the forced swim test, which is itself of questionable validity.
Fawn-Hooded
The Fawn-Hooded (FH) rat strain exhibits hypercortisolaemia and a blunted response to dexamethasone-induced suppression of cortisol secretion [87] consistent with the hyperactivity of the HPA axis which is observed in depressive illness. The elevated levels of plasma cortisol are reduced by chronic treatment with the TCAs imipramine and clomipramine, and with the MAO-A inhibitor, clorgyline [88] . FH rats also exhibit reduced growth rate consistent with an abnormality of the hypothalamic-somatotrophic (HSM) axis [89] . FH rats exhibit increased immobility in the forcedswim test in some studies (but not all; see [90, 91] ) and increased ethanol intake and preference [92] . Furthermore, ethanol consumption in FH rats is increased by social isolation [93] . Recent studies also indicate higher levels of anxiety in FH rats [94, 95] together with impaired social behaviour [96] . These observations indicate that the FH rat may be a suitable model of comorbid depressive illness, alcoholism and anxiety, but clearly, much more work is needed to substantiate this conclusion.
Like FSL rats, FH rats exhibit supersensitivity to ACh [92] . In contrast, FH rats exhibit functional hyposensitivity to a variety of 5-HT and NA receptor agonists [97, 98] reflecting altered serotonergic and noradrenergic function in the FH strain.
Models of Depression as a Response to Adversity (i.e. Stress)
A variety of adverse events have been used to produce animal models of depression, based on the observation that in general, the behavioural effects of stress are reversible by antidepressant drugs. However, the extent to which these effects meet the criteria for predictive validity, and the quality of the resulting models in terms of face and construct validity, varies greatly. For ease of presentation, we have grouped the models reviewed according to the nature of the stressor: acute experimenter-applied stressors; chronic experimenter-applied stressors; and models based on social stress and social isolation.
Acute Stress Learned Helplessness
As noted earlier, the learned helplessness paradigm is based on the observation that animals exposed to uncontrollable stress (usually electric shocks) are subsequently less able to learn to escape shock than animals exposed to comparable, or indeed, identical, patterns of controllable shock. The protective effect of control appears to result from lower levels of fear [99] , which raises important questions about the relationship between depression and anxiety. Seligman [33] proposed that exposure to uncontrollable stress provides the basis, in animals as in people, for learning that stress is uncontrollable (helplessness), and that this learning has a number of debilitating consequences, including depression. However, this interpretation has been the subject of considerable controversy, in both the human [100, 101] and the animal [30, 38, 102] literature and is probably incorrect (see above, and [5, 103] ). Nevertheless, the learning difficulties that follow exposure to uncontrollable shock are reversed with reasonable selectivity by multiple acute, subchronic, treatment over 3-5 days with TCAs or atypical antidepressants [104] . SSRIs also appear to be effective, but only within a limited dose range [105] , as do a number of other potential antidepressants such as 5-HT 1A receptor agonists [106] , β-adrenoceptor agonists [107] although some of these effects have been disputed [108] and extracts of St John's wort (hypericum perforatum) [109, 110] . Interestingly, chronic, but not acute, treatment with lithium prevents the development of learned helplessness in rodents [111] . There are a few false positives, including the 5-HT 2 receptor antagonist, methysergide [112] , p-chlorophenylalanine (pCPA) [113] and piracetam [114] , while neuroleptics, stimulants, sedatives and anxiolytics are generally ineffective [104, 115] .
The learned helplessness paradigm shows many symptomatic parallels to major depression -so much so that it has been suggested that rodents subjected to uncontrollable shock could meet DSM diagnostic criteria [30] ! However, the learned helplessness paradigm is implemented in a variety of different ways in different laboratories, and the version of the paradigm giving rise to the broadest range of symptoms [30] uses extremely high shock levels (4-6ma) which are of doubtful relevance to depression. Furthermore, the effects of this regime largely dissipate within 2-3 days, and the effects of antidepressant pretreatment have not been studied using this procedure. The effects of antidepressants have typically been studied using shocks of a considerably lower intensity (1.0-1.5ma) which cause a far less pervasive pattern of behavioural impairment.
Paradoxically, the effects of lower intensity shock are of longer duration, making it possible to interpose multiple acute (subchronic) drug treatment (typically for 3-5 days) between the initial uncontrollable shock session and the learning test. Furthermore, the duration of learned helplessness may be prolonged indefinitely by repeatedly exposing the subjects to the environment in which they had previously been subjected to the inescapable shock [116] , an observation which strengthens the face validity of this model of depression. However, a further problem is that different components of the learned helplessness syndrome may be related to different aspects of the induction procedure. For example, a long-term (7 weeks) suppression of home-cage locomotor activity has been reported following a single shock session [117] , but this effect is unrelated to shock controllability, and so clearly distinct from other learned helplessness phenomena [118] . It is clear that the learned helplessness model should more correctly be considered as a mixture of paradigms, and care should be taken in generalizing conclusions between them.
Among the consequences of low-intensity uncontrollable shock is a poor performance of rewarded behaviour, which, as noted above, may be of particular relevance to melancholia. One manifestation of this effect in mice is a longlasting decrease in responding for brain stimulation reward (intracranial self stimulation: ICSS), which is specific to certain electrode placements, and therefore suggests a sub-sensitivity within reward pathways, rather than, for example, a motor impairment [119, 120] . Normal sensitivity to ICSS was restored by chronic, but not acute, treatment with TCAs [119, 121] . Interestingly, a long-lasting anhedonia is seen only if the animals are tested immediately after stress; otherwise the effect dissipates rapidly [119] . A related observation is that mild stressors, that are without effect in normal animals, may reinstate behavioural deficits resulting from an initial exposure to severe stress [122] . These studies suggest that it may be possible to develop conditioning models to mimic how the risk of depression is elevated for several months in the aftermath of a stressful life event.
Another important observation is that uncontrollable electric shock has variable behavioural effects (most of which are antidepressant-reversible) in different inbred mouse strains. To take an extreme example, in the C57BL/67 strain, uncontrollable shock severely impaired subsequent learning to escape shock, but had no effect on responding for brain stimulation reward, while the DBA/2J strain showed exactly the opposite pattern of deficits [120, 123] . These studies may provide a starting point from which to investigate the physiological mechanisms underlying individual differences in responses to stress.
Vollmayr & Henn [124] have recently described a procedure in which mild shocks induce learned helplessness in only some of the subjects, which may mimic the variable human predisposition for depressive illness. This procedure has been used as the basis for a selective breeding programme, which has produced a 'congenital learned helplessness' (cLH) and a 'congenital non-learned helplessness' strain. An impressive neuroimaging study of cLH rats recently reported that metabolism was decreased in dorsal frontal, medial orbital and anterior cingulate cortex, but increased in the subgenual region of the cingulate cortex [125] ; exactly these changes have been described in depressed patients [126, 127] . However, there are also anomalies: in particular, cLH rats show a decreased adrenocortical response to stress [128] . There is also uncertainty as to just what is being selected in the cLH breeding programme. cLH animals have been shown to exhibit stress-induced analgesia [128] , raising the possibility that an increase in pain threshold might provide a very simple explanation of their escape learning impairments. Furthermore, given the separation of shock-induced escape deficits and anhedonia in inbred mouse strains [120, 123] , there is no reason to assume that the cLH strain, which was bred by selecting on the basis of shock-induced escape deficits, would also exhibit shockinduced anhedonia.
There is a relatively extensive literature dealing with the neurochemical bases of stress-induced motor inactivation (see [12, 129] ). Briefly, the debilitating effect of uncontrollable stress on later performance may be reversed by agonists at µ-opioid, DA, α 1 -and β-adrenoceptors or by anticholinergic drugs; conversely, helplessness may be simulated pharmacologically by drugs that reduce DA and/or NA function, or by drugs that increase cholinergic function [122, [130] [131] [132] . Any influence of DA neurotransmission on learned helplessness appears to be mediated by the D1 receptor [133, 134] . Furthermore, reduced catecholamine neurotransmission, either by inhibition of catecholamine synthesis with α-methyl-ρ-tyrosine [135] or by treatment with α 1 -and β-adrenoceptor antagonists (as well as the opiate receptor antagonist naloxone) has been shown to block the therapeutic effect of TCAs [136] . Similarly, blockade of NMDA receptor-mediated neurotransmission also blocks TCAinduced reversal of learned helplessness [137] . GABA neurotransmission also seems to be involved in learned helplessness behaviour. Thus a long-term increase in GABA B neurotransmission is associated with exacerbation of learned helplessness, while the action of antidepressant drugs in this model is associated with a long-term reduction in GABA B neurotransmission [138, 139] . In contrast, studies of the role of 5-HT in learned helplessness are inconsistent (see [5] ). Some 5-HT receptor agonists may reverse learned helplessness, while 5-HT lesions did not prevent the action of TCAs in this model [140] . The induction of behavioural depression/learned helplessness may be regulated, at least in part, by serotonergic input into the hippocampal CA3 subfield. Papolos et al. [141] have shown that intracerebroventricular administration of an antisense oligonucleotide to the 5-HT 2A receptor reduced receptor density in the CA3 area and induced learned helplessness behaviour.
Restraint Stress
Rats subjected to 2h restraint stress exhibit hypolocomotion when examined in an open field 24h later. Chronic treatment with DMI or sertraline prior to restraint stress reverses the hypolocomotion [142] . There is little basis on which to evaluate the validity of this model, which is included here simply to illustrate the generality of the reversibility of stress effects by antidepressants.
Chronic Stress
Chronic Severe Stress
Repeated presentation of the same stressor usually leads to adaptation. However, adaptation can be prevented by presenting a variety of stressors in an unpredictable sequence. Katz and colleagues [143] showed that three weeks of exposure to electric shocks, immersion in cold water, immobilization, reversal of the light/dark cycle and a variety of other stressors, caused a decrease in the activating effect of acute stress in an open field test. However, the activating effect of acute stress was maintained in animals receiving daily antidepressant treatment during the chronic stress period; the effects of administering antidepressants after exposure to stress have not been studied in this model. A variety of antidepressant drugs, as well as ECS, were found to prevent the effect of chronic stress, but the MAOI tranylcypromine was ineffective. In contrast, some psychotropic drugs lacking antidepressant activity failed to prevent the effect of stress. In addition to causing changes in open field activity, chronic stress also increased plasma corticosteroid levels. This effect showed the same spectrum of pharmacological sensitivity, with the exception that an anticholinergic was also effective [143] (see also [5] for review). Similar effects have also been reported in mice; corticosteroid levels and the response to an acute stress were normalized by TCAs, but not by the SSRI, fluoxetine [144] .
A further effect observed in rats after chronic stress was a failure to increase fluid consumption when saccharine was added to the drinking water, suggesting that chronic stress might cause anhedonia; this deficit was partially restored by imipramine [145] . The chronic stress model has been used very little since the original series of publications, in part because the levels of severity employed raise serious ethical problems. However, a variant of the model has been devised which employs very mild stressors.
Chronic Mild Stress
The CMS model was developed in an attempt to achieve the same endpoints as the chronic stress model, but in an ethically more acceptable manner. The procedure involves relatively continuous exposure of rats or mice to a variety of mild stressors, such as periods of food and water deprivation, small temperature reductions, changes of cage mates, and other similarly individually innocuous, but unpredictable, manipulations. Over a period of weeks of chronic exposure to the mild stress regime, rats gradually reduced their consumption of a preferred dilute sucrose solution, and in untreated animals, this deficit persisted for several weeks following the cessation of stress [39, 146] . As discussed earlier (see Construct Validity), various studies have been performed to confirm that these effects reflect a generalized insensitivity to reward; in particular, chronic mild stress also impairs responsiveness to reward as assessed by different methods, including suppression of place preference conditioning [147] [148] [149] and increased threshold for ICSS [43] . Studies of the effects of the individual elements of the chronic mild stress regime revealed that one element, social housing (in animals usually housed individually) was particularly potent, but no individual element (including social housing) was either necessary to induce, nor sufficient to maintain, anhedonia for a prolonged period [41] .
Antidepressant treatment has no effect on sucrose consumption or ICSS threshold in nonstressed animals, but following the reduction of sucrose intake by stress, normal behaviour was gradually restored by chronic treatment (twofive weeks) with a wide variety of antidepressants, including TCAs, SSRIs, a specific NA reuptake inhibitor (maprotiline), MAO-A inhibitors, atypical antidepressants such as mianserin, buspirone, and amisulpride, and ECS. Also effective were some agents of uncertain antidepressant status, such as antihistaminic and anticholinergic drugs. Ineffective drugs include the anxiolytic chlordiazepoxide, various neuroleptics, amphetamine, and morphine (see reviews [40, 150] ). Fluoxetine, maprotiline and mianserin (but not chlordiazepoxide) were also found to restore the rewarding properties of food, as assessed in the place conditioning paradigm [151, 152] . In contrast to the extensive array of drugs correctly classified in CMS experiments, very few false positives or false negatives have been reported.
The reversal of an established behavioural deficit during the continued presence of the stressor is an important feature of this model: if, as seems likely, chronic stress does play a role in the aetiology of melancholia (e.g. [26, 153, 154] ), its continued presence during antidepressant therapy would usually be the norm. Also important is the extended timecourse of antidepressant action, which makes it feasible to detect rapid onset of action. Many novel agents have been identified as potential antidepressants using the CMS procedure, and these include some that appear to act more rapidly than TCAs or SSRIs, including the D2/D3 receptor antagonist amisulpride [155] , the glycine antagonist 1-aminocyclopropanecarboxylic acid (ACPC) [156] , the 5-HT 1A receptor agonist BIMT-17 [157] , and the SNRI venlafaxine (Papp, personal communication) . Evidence indicates that the antidepressant efficacy of the SSRI citalopram resides in the S(+)-enantiomer, escitalopram [158] . Recent studies have shown that escitalopram exhibits a more rapid onset than racemic citalopram in the CMS model of depression [159] . Furthermore, the same studies demonstrated that R(-)-citalopram counteracted the behavioural effects of escitalopram. The mechanism by which R(-)-citalopram blocks the effects of the S(+)-enantiomer remains unclear but may be relevant to the improved and faster clinical antidepressant efficacy of escitalopram compared to citalopram. Potentiation of antidepressant action by lithium and pindolol has also been reported [160, 161] . In at least three instances (the D2/D3 receptor agonist pramipexole, the corticosterone synthesis inhibitor ketoconazole, and the catechol-O-methyl transferase (COMT) inhibitor tolcapone), the antidepressant effect of these compounds was demonstrated in the clinic only after these actions had been predicted in the CMS model (see [40] ).
In addition to decreasing responsiveness to rewards, CMS also causes the appearance of many other symptoms of major depressive disorder. Behavioural changes in animals exposed to CMS include decreases in sexual, aggressive, and investigative behaviours, and decreases in locomotor activity. These are seen during the dark phase of the light-dark cycle, which is the rat's active period; EEG measures of active waking are also decreased during the dark phase. In contrast, CMS did not cause the appearance of an 'anxious' profile in two animal models of anxiety, the elevated plusmaze and the social interaction test, suggesting that the behavioural changes are specific for depression. Animals exposed to CMS show an advanced phase shift of diurnal rhythms, diurnal variation in symptom severity (with peak severity at the start of the dark (active) phase), and a variety of sleep disorders characteristic of depression, including decreased REM sleep latency, an increased number of REM sleep episodes, and more fragmented sleep patterns. They also gain weight more slowly, leading to a relative loss of body weight, and show signs of increased activity in the HPA axis, including adrenal hypertrophy and corticosterone hypersecretion. Abnormalities have also been detected in the immune system, including an increase in serum, decreases in thymus weight, natural killer cell activity and reactivity to Tcell mitogens, and an increase in acute phase proteins that was reversed by chronic antidepressant treatment. Taken together with the generalized decrease in responsiveness to rewards, these parallels to the symptoms of depression, and in particular, to melancholia, are both extensive and comprehensive (reviewed in [40] ). Indeed, it is arguable that the only symptoms of depression that have not been demonstrated in animals exposed to CMS are those uniquely human symptoms that are only accessible to verbal enquiry. Even without these symptoms, a rat exposed to CMS could, in principle, legitimately attract a DSM-IV diagnosis of either major depressive disorder or major depressive disorder with melancholic features.
Studies of the neural basis of the CMS-induced anhedonia have focused primarily on the mesolimbic DA system. The behavioural changes in animals subjected to CMS are accompanied by a decrease in D2/D3-receptor binding and D2-mRNA expression in the nucleus accumbens, and a pronounced functional subsensitivity to the rewarding and locomotor stimulant effects of the D2/D3 receptor agonist quinpirole, administered systemically or within the nucleus accumbens. All of these effects are also reversed by chronic antidepressant treatment [150, 162] . In other studies, animals successfully treated with antidepressants were treated acutely with D2/D3 receptor antagonists, at low doses that were without effect in non-stressed animals or in untreated stressed animals. This treatment reversed the effects of a wide variety of antidepressants on rewarded behaviour [150] . These data argue strongly that an increase in D2/D3 receptor responsiveness may be responsible for the therapeutic action of antidepressants in this model [150] . A similar reversal of SSRI action by the D2 antagonist sulpiride has been observed in a clinical study, as predicted from the CMS data [40] .
While the CMS model has a great many positive features, and is probably the most valid animal model of depression currently available (see below), a major drawback is that the model has proved extremely difficult to implement reliably, and while many laboratories have succeeded in doing so, many others have not. The reasons for this lack of reliability have been extensively debated (see [40] ), but as yet are unresolved.
Stress Induction and Mild Stress Maintenance
Tagliamonte and colleagues have described a model that represents a cross between learned helplessness and CMS [163, 164] . In this procedure, an altered state is first induced by acute exposure to a session of moderately intense inescapable tail shock, and then maintained, apparently indefinitely, by exposure to milder stressors (brief restraint, a small number of shocks, or exposure to the inescapable shock apparatus but without shock), presented at two-day intervals. This treatment resulted in an impairment of shock escape learning, as in learned helplessness, and a failure to learn a simple maze task reinforced by a highly palatable food (vanilla sugar), as in CMS. Both of these deficits were prevented by chronic pretreatment with TCAs or fluoxetine [163, 164] . The stress procedure also decreased basal levels of extracellular DA in the nucleus accumbens shell, and this change also was prevented by chronic TCA treatment [165] .
Withdrawal from Chronic Psychomotor Stimulants (Amphetamine Cocaine)
A number of studies have reported that ICSS responding was reduced in the days following withdrawal from chronic amphetamine treatment. In these studies, amphetamine was administered to rats for between 4 and 10 days, typically using several administrations each day, at increasing doses [166] [167] [168] [169] . The threshold for ICSS was elevated following amphetamine withdrawal, confirming that the rate reduction reflects a subsensitivity to brain stimulation reward rather than a depression of motor activity [170, 171] . In a single pharmacological study, this effect was alleviated by two days of imipramine or amitriptyline treatment, and with continued treatment, normal responding was restored [172] .
In a variant of this procedure, animals self-administer cocaine, rather than being administered amphetamine [173] . In these experiments, the threshold for brain stimulation reward, administered through electrodes in the posterior lateral hypothalamus, was obtained using a discrete trial procedure [174] , which is sensitive to changes in reward value, but not to changes in motor performance [175] . Following 24h of cocaine self-administration, ICSS thresholds were elevated for several hours [173] , indicating that cocaine withdrawal induced a state of anhedonia. Acute administration of the DA receptor agonist, bromocriptine, restored ICSS thresholds to normal [176] . Only one conventional antidepressant has been tested in this procedure: repeated administration of the TCA, DMI, was reported to shorten the duration of post-cocaine anhedonia [177] .
It has frequently been assumed that stimulant drug treatment is a form of stress, since in many respects stimulant treatment and stress appear to be interchangeable [178, 179] . Indeed, withdrawal from chronic cocaine treatment in rats is associated with intense anxiety-related behaviour and extrahypothalamic-limbic CRH hypersecretion [180] . The similarities between stress and stimulant withdrawal are thought to arise from the fact that, like stimulant drugs, stressors activate the mesolimbic and mesocortical DA projections [181] . Independent of a relationship to stress, there is an obvious parallel between the effects of stimulant withdrawal and the depressions that frequently follow the cessation of chronic stimulant use [182] , though in the animal model, the time course is rather more compressed.
As the stimulant withdrawal models are based exclusively upon changes in ICSS behaviour, their construct validity depends largely on the assumption that brain stimulation reward activates natural reward pathways [183] . Although early studies suggested that ICSS had unusual properties compared to natural rewards (for example, rapid extinction), it was later recognized that these properties derive from differences in the experimental procedures typically employed (such as the delay of reinforcement); when such extraneous factors are equated, ICSS appears very comparable to a high incentive natural reward presented under conditions of low drive (e.g. see [184] ). These parallels, together with the observation that ICSS responding is influenced by many of the factors that control responding for natural rewards, have justified the assumption that the ICSS electrode stimulates directly the neural substrates that are activated indirectly by natural rewards [183] . A degree of caution is required, since although people implanted with ICSS electrodes report a variety of pleasurable sensations, they also report other reasons for stimulating, such as curiosity [185, 186] . Nevertheless, the commonality of anatomical substrate between ICSS and other types of reward supports the use of this procedure as an animal model of hedonic behaviour (see also [173, 187] ). However, the relationship of drug-induced depressions to major depressive disorder is uncertain, and the validity of this model is therefore questionable.
Social Dominance Models
Parallels have often been noted between depressive and submissive behaviours [188, 189] , and a number of laboratories have attempted to model depression by using animals of low social rank. Subordinates, and those who have lost status as a result of defeat in social conflict situations, are at greater risk of psychopathology. Biological similarities between defeated animals and human depression have frequently been noted (e.g. [190] [191] [192] ), and there is considerable evidence that depressed individuals see themselves as inferior and behave submissively (reviewed in [192] ). Indeed, social skills training, of which assertiveness training represents a major component, is used clinically as a psychotherapy for depression, and has been found to be equally effective as TCA treatment (e.g. [193] ). Like the chronic mild stress procedure, animal models based on social dominance employ realistic inducing conditions, which are of particular ecological and ethological relevance.
Social Separation
The presumed aetiological role in depression of loss events, and particularly, loss of a loved one, has led to the development of a number of animal models of depression based on separation phenomena.
Although the evolutionary proximity of primates has led some authors to consider primate separation models to be of particular importance (e.g. [194] ), they have produced remarkably little of value. Precisely because of their evolutionary proximity, the use of primates sacrifices many of the advantages of animal models, such as the easing of ethical constraints, and the possibility of testing adequately sized groups of subjects.
Neonatal Isolation
The most familiar of these models involve non-human primates, either infants isolated from their parents, or juveniles isolated from their peer group. The separation response consists of an initial stage of 'protest', characterized by agitation, sleeplessness, and distress calls, followed by 'despair', characterized by a decrease in activity, appetite, play and social interaction, and the assumption of a hunched posture and 'sad' facial expression (see [2, 195] ). These symptoms are strikingly similar to those of 'anaclitic depression' in institutionalized children [196] . However, while parental loss in childhood, and loss events such as bereavement in adults, are implicated in the etiology of depression, they also increase the risk of a variety of other psychiatric and non-psychiatric disorders [197, 198] . The nature of the separation response is sensitive to the environment in which the experiments are carried out [195, 199] , and the incidence of 'depressive' behaviours may in some experiments be as low as 15% [200] .
Results from the few pharmacological studies using these models have not been impressive. Very few published studies have attempted to use antidepressant treatments to modify primate separation behaviour, and because of the expense of using primates, the size of experimental groups in most studies has usually been too small to provide reliable data. Chronic treatment with DMI [201] , imipramine [202] , oxaprotiline [203] and ECS [204] have been reported to reverse some, but not all, of the effects of separation in monkeys. Trifluoperazine, amphetamine and diazepam did not affect responses to social isolation in chimpanzees [205, 206] , but some therapeutic effects of chlorpromazine were seen in Rhesus monkeys [207] . 'Depressive'-like behaviours in singly-housed Rhesus monkeys are associated with decreased concentrations of NA in the cerebrospinal fluid, with relatively little effect on DA or 5-HT [208] . Following a return to social housing, NA levels normalize, but the animals remain hypersensitive to pharmacological challenges of the NA system [209, 210] .
In fact, separation phenomena of 'protest' followed by 'despair' are present to some extent in many other species, including cats, dogs, rodents and precocial birds [211, 212] , and several of these phenomena have also been used as the basis for the development of animal models of depression. One of these, the reactivation of distress calling in one-week old chicks, appears to perform relatively well as an antidepressant screening test [213] . The vocalizations of guinea-pig pups separated from their mothers also respond to antidepressants, and this test predicted the antidepressantlike activity of the Substance P neurokinin 1 (NK1) receptor antagonists [214] 
Adult Isolation
Chronic (4-6 weeks) isolation of adult rats has been found to cause a disruption of cooperative social behaviour [215] reminiscent of the poor social performance of depressed people [216] . In a single study of the effects of antidepressant treatment, the impairment of social cooperation in isolated rats was reversed by chronic treatment with either imipramine or fluoxetine, and the effect of imipramine in this model was abolished by the 5-HT antagonist, metergoline [217] .
Social Defeat
Social defeat is a potent stressor, and repeated defeat is a form of chronic stress, which is associated with a decrease in aggressive behaviour [218] . A single social defeat has been reported to produce a gradual, but long-lasting, increase in immobility in the forced swim test, which was prevented by chronic treatment with clomipramine [219] . A similar model has been developed in submissive C57BL/6J mice: a single defeat by a dominant male mouse of the same strain was reported to cause a gradual increase over weeks in passive behaviour in response to a mild stressor, which could be antagonized by clomipramine; defeated animals also had higher immobility times in the forced swim test [220] . In a chronic version of a similar procedure, mice were housed in social contact, but were physically separated except for one daily 3-minute encounter. Again, increased immobility in the forced swim test was observed in repeatedly defeated animals, and this effect was prevented by chronic treatment with imipramine [221] , though in this study, imipramine did not normalize social behaviour in the defeated animals.
In a modified rat model, defeat of dominant pair-housed rats by rats of a different, more aggressive strain resulted in the loss of dominant status relative to their previously submissive partners, which was restored by chronic imipramine treatment [222] . This loss of status was accompanied by the abolition of morphine-induce place conditioning, most likely reflecting a decrease in hedonic tone [223] . This suggests that it may be appropriate to view submission models as potential models of melancholia. However, more evidence is needed for any firm conclusion.
In a modified murine social defeat paradigm, subordinate mice subjected to repeated social defeat showed reduced growth compared to dominant subjects, together with citalopram-sensitive anxiogenic-like behaviour [224, 225] . The defeated mice exhibited a maintained increase in both core temperature and circulating corticosterone levels indicative of chronic stress, although social defeat had no effect on either ethanol consumption or immobility time measured in the forced swim test. Similarly, a single social defeat of Lewis rats resulted in hypophagia and weight loss together with increased measures of anxiety; effects which were reduced following chronic (21 day) fluoxetine treatment [226] .
Overall, these various studies suggest that social defeat may in principle provide a valid and ecologically sound model of depression. However, a variety of procedures have been used, and at present, the data are not entirely consistent.
Agonistic Behaviour
The ethological studies of Dixon and co-workers [227] have shown that increased flight and impaired sociability are significant features of the non-verbal behaviour of patients with depressive illness. Clinical studies also indicate that such abnormal behavioural responses/reactions of patients with depressive illness to environmental and social stimulation are progressively modified during remission from the illness [228] [229] [230] . Thus recovery from a depressive episode is associated with progressively reduced self-criticism and feelings of guilt [231] that lead to increased physical and/or verbal interaction with the environmental and social events [232] . The reversal of impaired sociability may therefore be an important index of the recovery process from depressive illness. The ability of antidepressant treatments to modify the behavioural responses of patients with depression has generally been ignored in the search for a definitive animal model of depressive illness. The resident-intruder paradigm (see section 3.4.3.1) provides a means to examine the ability of psychotropic drugs to modify the social and agonistic behaviour patterns of laboratory rodents. The experimental paradigm relies exclusively on the concepts and techniques of ethological analysis of rodent behaviour since ethology provides a method of precise and quantitative assessment of natural patterns of animal behaviour.
Ethology is defined as the science or study of the function and evolution of animal behaviour, and is typically concerned with the analysis of natural action patterns of animal behaviour in a natural environment. Early ethological studies examined how the behaviour of animals in their natural environment contributed to the survival of both the species in general, and the individual animal in particular. It was only during the late 1950s and early 1960s that Chance and co-workers first recognized the utility of natural action patterns of behaviour in the study of both the behaviour of laboratory animals per se and the behavioural effects of drugs. Their publications from this time have become landmarks in the development of ethological techniques to study the behaviour of laboratory animals [233] [234] [235] [236] [237] . Over the last 40 years (and especially during the last 20 years with the rapid advances in computer technology to facilitate data recording and analysis) ethological concepts and methods have been employed and refined by various groups.
A major problem in observing animal behaviour, especially when using social behaviour as a pharmacological tool, is to ensure that the subject animals perform at an intensity and at a time required by the experimenter. The environment plays an important role in determining which behaviours a given species is predisposed to display. Lighting conditions [238] , social experience and familiarity of partner(s) [239] [240] [241] [242] , familiarity of experimental arena [238] , territorial advantage [242, 243] and hierarchical position within a closed social group [244, 245] all affect the social behaviour of rats (for further discussion on the impact of social and environmental conditions on rodent behaviour see [246] ).
Rats are nocturnal and thus generally quiescent during the light phase of the light-dark cycle and active during the dark phase. To identify and record as many behaviours and postures from a subject's behavioural repertoire as possible observations should be made when subjects are most active. For nocturnal animals therefore, determination of the effect of psychotropic drugs on natural action patterns of behaviour should employ observations during the dark phase of the light-dark cycle. In most cases, for the convenience of the experimenter, this necessarily means that rats must be fully entrained to a reverse light-dark schedule so that observations during the active phase of the animals can be made during the wake phase of the observer! The structure of social behaviour in a number of different orders of vertebrates is dependent on the agonistic behaviour appropriate to the antagonism between males. When male laboratory rats are housed in closed social groups such behaviour results in the males becoming ranked [233] . The respective rank position of each group member is related to their level of aggressive behaviour when they are initially housed together. Thus higher aggressors achieve higher rank positions. Generally, the social hierarchy develops over a period of about two to three weeks, but once established both the hierarchical structure and the level of aggressive behaviour exhibited by each group member remain essentially constant [236] . Furthermore, a rat's rank position appears to be maintained through success in social and agonistic encounters with the cage partners [245] .
Both domesticated and in-bred strains of male rat exhibit agonistic behaviour to defend their territory when confronted with an unfamiliar intruder conspecific [243] . The term 'agonistic behaviour', first used by Scott [247] , refers to the spectrum of conflict-related behaviours, including not only aggressive behaviours, but also the elements indicative of escape, defence and submission. Even under laboratory conditions the agonistic behaviour of in-bred laboratory rats contains all the behavioural elements of the agonistic behaviour of wild rats [248] . If two rats are placed in a neutral environment where neither rat has a territorial advantage, then very few aggressive episodes will be observed, even if the active contact is quite intense [242] . In contrast, if an unfamiliar intruder conspecific is introduced into the home cage of an isolated resident rat, then intense social and agonistic behaviour will ensue. Such behaviour is initiated predominantly by the resident rat and is indicative of the degree of territorial advantage enjoyed by the resident rat over the intruder. Such territorial advantage is apparent after the resident rat has been singly housed for only a few days.
The effect of psychotropic drugs on social and agonistic behaviour may depend on the social position of the treated subject [241, 249] . If the social position of an animal predetermines that animal's response to psychotropic drugs then a significant contribution to 'biological variation' or 'experimental error' may simply reflect the differential responses of animals in different social positions. Indeed, Silverman [237] argued the case for using stable social groups in behavioural experiments. All too often these important behavioural variables have been ignored in behavioural research.
Resident-Intruder Paradigm
In consideration of the environmental and social issues described above, a resident-intruder paradigm has been developed which has proved particularly useful in demonstrating the effects of antidepressant drugs on rodent social and agonistic behaviour.
In the resident-intruder paradigm all animals are housed under reverse-daylight conditions for at least 5 weeks from weaning before the start of each experiment to allow full entrainment to the reverse-daylight cycle. In all studies the resident and intruder rats are obtained from different parental groups to ensure that all social encounters are between rats that are unfamiliar to each other. Furthermore, both resident and intruder groups of rats are housed in closed social groups (n=4 per group) for at least three weeks prior to and throughout each experiment. This not only allows the development and maintenance of a stable social hierarchy in each group but also provides constancy of social experience from the same time point following weaning [239, 240, 242] . In all studies only resident rats receive drug or vehicle, and two groups of resident rats are used to provide n=8 for each treatment group.
To profile fully the effect(s) of a compound on rodent non-social, social and agonistic behaviour, three experimental designs for the resident-intruder paradigm have been developed.
1) Acute Treatment 2) Chronic Treatment 3) Time-Course
Although not the primary focus of this review it is important to note that acute treatment studies with psychotropic drugs are an important precursor to subsequent chronic treatment studies since they provide invaluable information on drug potency and enable behaviourally-active doses of compounds to be identified. Since previous social experience may profoundly affect an animal's subsequent behaviour it is important to contrast the effects of acute and chronic treatment with psychotropic drugs using groups of animals whose social experience is as similar as possible. In both acute and chronic treatment studies each group of animals are tested on four occasions only, on a weekly cycle. Resident rats are isolated for three days prior to each test day and housed individually with food and water available ad libitum. At the start of each social encounter test the home cage containing the resident rat is positioned inside the recording cabinet (for details see [250] ) for at least 30 min following which the intruder conspecific is introduced. The ensuing social encounter is recorded on video tape for 10 min under low-intensity (0.5 -4 lux at the cage floor) red light illumination by a video camera positioned above the recording cabinet. At the end of each recording session both resident and intruder rats are returned to their respective group cages.
In acute treatment studies resident rats are treated with drug or vehicle prior (typically 30 -60 min) to each social encounter and returned to their respective home cage. In each study resident rats receive four treatments (drug-vehicle and three doses of drug) and encounter each of the corresponding intruder conspecifics over the four test sessions. In chronic treatment studies resident rats are behaviourally tested on the first occasion without any treatment to provide a baseline behavioural profile, following which osmotic mini-pumps are implanted (usually subcutaneously). Social encounters are performed 7 and 14 days later, after which the mini-pumps are removed. The final social encounter is then performed 7 days after the cessation of drug treatment. Similarly, resident rats in chronic treatment studies encounter each of the corresponding intruder conspecifics over the four test sessions.
In the time-course studies, resident rats (initially 2 groups of 4 rats per group; each resident group with a corresponding intruder group) are subjected to eight social encounters. These animals are also isolated for three days prior to the first test day and housed individually with food and water available ad libitum, but remain isolated throughout the duration of the experiment. Again, resident rats are behaviourally tested on the first occasion without any treatment to provide a baseline behavioural profile, following which osmotic mini-pumps are implanted. Social encounters are then performed at daily intervals and arranged to ensure that each resident rat meets each of the corresponding 8 intruder conspecific rats over the test sessions. In this way the onset of drug-induced changes in rodent behaviour may be monitored during the first week of treatment.
During ethological analysis of rodent behaviour the occurrence of each behaviour or posture exhibited by the resident rats during each social encounter are identified and recorded during video playback. The scores for each behaviour/posture are grouped according to their motivational category (see Table 2 ) for each animal and the total score for each category expressed as a percentage of the total number of behaviours observed for that animal. The data from the two groups of four resident rats are grouped and the mean and standard error of the mean are calculated for both the percentage values of each motivational category and the total number of behaviours/postures observed within each treatment group. In a typical 10 min social encounter resident rats will exhibit between 1200 and 1500 behavioural elements. The rapid change from one behavioural element to another means that frequency measures of behaviour are more appropriate than time measures (i.e. the total time associated with one individual behaviour or the total duration spent expressing a group of behavioural elements). Fig. (1) provides a typical example of the behavioural profile of resident rats (Mitchell, data on file). Invariably resident rats exhibit high levels of investigatory behaviour (about 50% of all behaviours scored) directed at the intruder conspecific following introduction of the latter into the resident rat's home cage. In some cases such intense conspecific investigation leads to the expression of aggressive behaviour directed at the conspecific (about 5% of total behaviours) or flight behaviour (total flight behaviour equals about 15% of total behaviours scored). Flight behaviour in the rat may be subdivided into two flight pathways; flight submit and flight escape. In these studies the occurrence of flight escape behaviour invariably far exceeds flight submit behaviour Fig. (1) . Behavioural profile of resident rats expressed during social encounters with unknown intruder conspecifics. Individual elements of the behavioural repertoire are grouped according to motivational category (see Table 2 ) and expressed as a percentage of the total number of behavioural elements scored for each individual animal. The mean and SEM of the percentage values for 8 resident rats were then calculated for each category of behaviour. In this example the mean (± SEM) total number of behavioural element = 1458.4 ± 78.7.
Motivational categories of behaviour: Exp indicates cage exploration, Main indicates maintenance behaviour, Inv indicates investigatory behaviour directed at the conspecific intruder, Sex indicates sexual behaviour directed at the intruder, Agg indicates aggressive behaviour directed at the intruder, Fsub and Fesc indicate flight submit and flight escape behaviours, respectively, directed away from the intruder.
(12-14 % c.f. 1-2%) and reflects the opportunity to flee afforded by the size of the cage in which the social encounter takes place. The remaining categories of behaviour (maintenance and sexual behaviour) occur very infrequently (about 1% of total behaviours scored in both cases). 2) shows the effect of acute treatment with venlafaxine, 5.5 -50 mg/kg sc, on the behavioural profile of resident rats expressed during social encounters with unfamiliar intruder conspecifics. Compared to saline-treated controls, acute treatment of resident rats with increasing doses of venlafaxine induced a dose-related decrease in the aggressive behaviour of resident rats directed at the unfamiliar intruder conspecifics, concomitant with increased flight escape behaviour. None of the doses of venlafaxine examined significantly modified any other category of behaviour, including the total number of behavioural elements expressed by resident rats (see Fig. (3) ). The ability of venlafaxine to reduce aggressive behaviour and increase flight escape behaviour at doses devoid of effect on the total number of behaviours expressed during social encounters (see Fig. (4) ) indicates that venlafaxine has a selective (i.e. non-sedative) effect on rodent agonistic behaviour. Indeed, an ability to reduce aggressive behaviour and invariably increase flight behaviour of resident rats in this paradigm following acute treatment is an ability shared by all pharmacologically disparate antidepressant compounds tested (Table 3) , including examples of SSRIs, SNRIs, MAOIs, TCAs and atypical drugs such as mianserin and iprindole. In contrast, almost without exception psychotropic drugs with no recognized clinical efficacy in depressive illness either have no effect on rodent agonistic behaviour or only reduce aggressive behaviour at doses which cause marked reductions in total behaviour score (e.g. diazepam, haloperidol, phencyclidine, Table 3 ), indicative of motor impairment (i.e. sedation). It is therefore possible that an ability to selectively reduce aggressive behaviour following acute treatment may be related to a drug's antidepressant efficacy. This being so, then these data predict that amphetamine together with 5-HT 1A receptor agonists and partial agonists, e.g. 8-hydroxyn, n-dipropyl aminotetralin (8-OH-DPAT) and gepirone, and 5-HT 2C receptor agonists, e.g. m-chlorophenylpiperazine (mCPP), but not antagonists for these serotonin receptor Summary of the various elements of rat behaviour, grouped according to motivational category, expressed by rats during social encounters. Adapted from Grant [234] . *These behaviours are not recorded in resident-intruder studies described here. Full mating behaviour is not possible between male cohorts, while food and water are not available during each social encounter.
subtypes (e.g. WAY-100635 and mesulergine, respectively) possess antidepressant activity. In addition, resident-intruder studies also suggest that the antidepressant efficacy of citalopram resides in the S(+)-enantiomer (see Table 3 ) in agreement with other behavioural studies using the CMS model [159, 251] . Some studies using the learned helplessness model of depression have suggested that antagonists of the octapeptide angiotensin II (AT) may possess antidepressant activity. In particular, it has been proposed that blockade of AT 1 receptors by the selective antagonist losartan may have an antidepressant effect [252] . Likewise, studies have shown that antagonists of the cholecystokinin B (CCK B ) receptor reduce immobility time in the murine forced swim test predictive of antidepressant activity [253] . In the resident-intruder paradigm, however, acute treatment with selective antagonists at AT 1 receptors (losartan and ANA-756), AT 2 receptors (PD-123177), CCK A or CCK B receptor antagonists (devazepide and L-365260) all failed to modify rodent agonistic behaviour (see Table 3 ) at doses similar to those shown to induce antidepressant-like changes in behaviour in other models. The resident-intruder paradigm therefore predicts that these compounds will be devoid of Individual elements of the behavioural repertoire were grouped according to motivational category (see Table 2 ) and expressed as a percentage of the total number of behavioural elements scored for each individual animal. The mean and SEM of the percentage values for 8 resident rats were then calculated for each category of behaviour. Compared to saline-treatment, venlafaxine induced a dose-related reduction in aggressive behaviour concomitant with increased flight escape behaviour. Post hoc analysis (Dunnett's test); ** P < 0.01, *** P < 0.001 c.f. saline control rats. Re-drawn from [257] .
antidepressant activity. However, such predictions are based on changes in rodent behaviour induced by acute drug treatment and, as previously discussed, such predictions should be treated with caution until the effect of chronic treatment with these compounds on rodent agonistic behaviour has been examined. Furthermore, we argued earlier that a failure to respond appropriately to ECS would severely question the predictive validity of the model (see Predictive Validity). Recent studies by our group [254] have shown that a single ECS markedly, and non-specifically, disrupts the behavioural profile of resident rats up to 4h following treatment. It is therefore unlikely that changes in the behavioural profile of resident rats following acute psychotropic drug or single ECS treatment are directly related to their antidepressant activity.
The observed changes in resident rat behaviour following acute drug treatment are useful in two respects, however.
First, such studies demonstrate that antidepressant drugs have a selective effect on rodent agonistic behaviour which is the primary criterion for identifying potential compounds of interest. Second, these studies allow behaviourally-active doses of a compound to be identified which may be used to examine the effect of chronic drug treatment on the behaviour of resident rats.
In chronic treatment studies, drugs are invariably administered by sc-implanted osmotic minipump loaded with drug at a concentration calculated to administer the desired dose over 24h for up to 14 days. In most cases the desired dose is defined as the minimal-effective dose determined in the acute treatment studies (see above). Drug administration by osmotic minipump was chosen as the most appropriate mechanism of chronic drug delivery since this obviates the need for excessive handling of the resident rats and therefore reduces both handling-associated stress and the possibility of taming the subjects by repeated exposure to the experimenter which may modify the subject's behavioural profile during subsequent social encounters. Finally, delivering drugs over extended periods of time by this mechanism means that the amount of handling experienced by animals used in the acute treatment and chronic treatment resident-intruder paradigms are very similar, and results in very similar baseline behavioural profiles of the resident rats used in these two paradigms.
In contrast to the changes in rodent agonistic behaviour induced following acute treatment with antidepressant drugs, chronic treatment with these compounds increases aggressive behaviour concomitant with reduced flight behaviour. Fig. ( 5) compares the behavioural profiles of two groups of resident rats during chronic treatment with saline and venlafaxine (5.54 mg/kg/day sc via osmotic minipump) respectively. Throughout the experiment saline-treated resident rats maintained a constant behaviour profile. However, compared to the respective baseline levels of each motivational category and also to the saline-treated resident rats at each time point, resident rats treated with venlafaxine exhibited increased aggressive behaviour concomitant with reduced flight submit and flight escape behaviour at both 7 an 14 days of treatment. No other significant changes in any category of behaviour were observed, including the total number of behavioural elements observed (data not shown). Chronic treatment with venlafaxine therefore induces diametrically opposite changes in the behavioural profile of resident rats compared to when this compound is administered acutely. Furthermore, an ability to increase the aggressive behaviour of resident rats is a common effect on behaviour observed during chronic treatment with antidepressant drugs regardless of the pharmacological action of these chemically disparate compounds (see Table 4 ) [250, 251, [255] [256] [257] [258] [259] [260] [261] [262] [263] [264] . Interestingly, ECS (which disrupted behaviour for up to 4 hours following a single shock) similarly increased aggressive behaviour when single shocks were administered every other day throughout the experiment [254] . This observation supports our earlier argument (see Predictive Validity) that an animal model predictive for antidepressant activity should show a positive response to repeated ECS. In contrast, amphetamine (which selectively reduced aggressive behaviour after a single dose predictive of antidepressant activity, see Table 3 ) failed to increase Fig. (3) . Effect of 30 min pre-treatment with venlafaxine, 5.54 -49.85 mg/kg sc (black columns), on the total number of behavioural elements exhibited by resident rats compared to the effect of acute saline treatment (open columns) during social encounters with unknown intruder conspecifics. Columns indicate mean and SEM of the total behavioural elements observed for 8 resident rats. Post hoc analysis (Dunnett's test); * P < 0.05 c.f. saline control rats. Re-drawn from [257] . Fig. (4) . Dose response curves to acute treatment with venlafaxine on aggressive behaviour (closed triangles) and total behaviour score (open triangles) exhibited by resident rats during social encounters with unknown intruder conspecifics. Percentage change from the behavioural profile exhibited by resident rats treated with saline calculated from data in Figs. (2 and 3) . Post hoc analysis (Dunnett's test); * P < 0.05, *** P < 0.001 c.f. saline control rats. Re-drawn from [257] .
aggression during the period of chronic treatment. Indeed, amphetamine, 10 mg/kg/day, induced behavioural changes characteristic of social withdrawal; a phenomenon more closely associated with the negative symptomatology of psychosis. Compounds which failed to modify the aggressive behaviour of resident rats following acute treatment similarly failed to modify behaviour during chronic treatment (e.g. the selective 5-HT 1A receptor antagonist WAY-100635). Overall, these observations are consistent with the view that aggression is the only type of rodent social behaviour consistently increased following chronic treatment with antidepressants [265] .
The resident-intruder paradigm coupled with ethological analysis of the resulting non-social, social and agonistic behaviour quite clearly shows that antidepressant drugs have very specific effects on rodent behaviour that are dependant on the duration of drug treatment. Thus, while acute treatment with antidepressant drugs selectively reduces aggressive behaviour, chronic treatment increases aggression, and in both cases such changes in aggressive behaviour are associated with reciprocal changes in flight behaviour. The fact that chronic antidepressant treatment increases aggressive behaviour appears at first sight to be incompatible with the use of SSRIs in the clinical treatment of impulsive Values indicate the doses calculated to reduce aggressive behaviour and total behaviour score by 50% (ID 50 doses, mg/kg sc). Where an ID50 value was not determined then the value indicates the highest dose tested. Antidepressant drugs invariably reduce aggression at doses lower than those required to reduce total behaviour score. Data on file unless otherwise indicated as follows; a [261] , b [251] , c [250] , d [257] , e [258] , f [256] , g [263] , h [262] .
aggression [266] [267] [268] . However, this is a clinical, rather than an experimental, paradox, since clinically, antidepressants both increase aggression in submissive depressed individuals (manifest as a reversal of intropunitive aggression and/or impaired sociability: see [227, 231, 232] ) and decrease pathological aggression (e.g. [269, 270] ). A resolution of this paradox may be that antidepressant treatment increases assertiveness, since this would increase low levels of social dominance while at the same time decreasing high levels of physical aggression. The ability of chronic antidepressant treatment to increase aggression in rats may reflect the increased assertiveness and associated externalization of emotions expressed during recovery from depressive illness. Such increased assertive/aggressive behaviour is consistent with the effects of such treatment in the social hierarchy model (see below). However, it should be acknowledged that the face validity of the resident-intruder model is reduced by the fact that the test involves 'normal' unmanipulated animals; non-depressed people do not respond to antidepressant treatment. Interestingly, and in contrast to the rat studies, the aggressive behaviour of male mice in resident-intruder studies is particularly sensitive to anxiolytic, rather than Fig. (5) . Effect of chronic treatment via sc-implanted osmotic minipump with saline (open columns) or venlafaxine (5.54 mg/kg/day; black columns) on the behavioural profile of resident rats expressed during social encounters with unknown intruder conspecifics. Individual elements of the behavioural repertoire were grouped according to motivational category (see Table 2 ) and expressed as a percentage of the total number of behavioural elements scored for each individual animal. The mean and SEM of the percentage values for 8 resident rats were then calculated for each category of behaviour. Saline-treated resident rats exhibited no change in their behavioural profile throughout the study. In contrast, venlafaxine-treated resident rats exhibited increased aggressive behaviour, concomitant with reduced flight behaviour after 7 and 14 days of treatment. Following the cessation of treatment the behavioural profiles returned to predose levels. Post hoc analysis (1 way-ANOVA); * P < 0.05, ** P < 0.01, *** P < 0.001 c.f. predose level of behaviour except where indicated. Re-drawn from [257] .
antidepressant, drug activity (e.g. [271] ). The reason for this species difference in responses to antidepressant and anxiolytic drugs most likely resides in the functional differences in aggressive behaviour between rats and mice. Mice will violently defend their territory while rats live in social colonies where excessively violent behaviour is detrimental to the social group.
By programming daily dyadic encounters, the residentintruder paradigm can also be used to compare the rate of onset of antidepressant-induced increases in aggression between antidepressant treatments and to assess the ability of potential adjuvant treatment to accelerate antidepressantrelated changes in rodent behaviour. Fig. (6) compares the aggressive behaviour of three groups of rats during 7 days chronic treatment with saline, venlafaxine (5.54 mg/kg sc) and fluoxetine (0.34 mg/kg/day sc). While the aggressive behaviour expressed by saline-treated animals remains essentially constant throughout the duration of the experiment, both venlafaxine-and fluoxetine-treated resident rats exhibit increased aggression by days 2 and 5 of treatment, respectively. Interestingly, the doses of venlafaxine and fluoxetine used in this study were the minimal-effective doses on rodent behaviour when administered acutely, and both are slightly less than their respective ID 50 values on rodent aggression (see Table 3 ). Even though the doses used in this latter study are therefore near-equipotent the timecourse data suggest that venlafaxine is able to increase rodent aggression more rapidly than fluoxetine. Further studies have shown that paroxetine (0.33 mg/kg/day sc), citalopram (1.0) and escitalopram (0.5) increase the aggressive behaviour of resident rats by day 5, 4 and 1, respectively, indicating that different antidepressant drugs have different rates of onset. However, it is possible that the rate of onset is a function of dose. In a further time-course experiment, the rate of onset of three doses of fluoxetine (0.34, 1.02 and 3.09 mg/kg/day sc) was compared. The results of this study (see Fig. (7) ) show that while fluoxetine, 0.34 mg/kg/day, increased aggression by day 5 (consistent with the earlier study) the two higher doses of fluoxetine both increased aggression by day 3. These data clearly indicate that while a more rapid response to fluoxetine may be obtained by increasing the dose form 0.34 to 1.02 mg/kg/day, this effect cannot be further reduced to less than 3 days irrespective of dose.
The delay in onset of antidepressant-induced changes in the behaviour of resident rats suggests that adaptive changes Values indicate the daily doses administered to the resident rats, by osmotic mini pump, and were based on doses previously shown to modify rodent behaviour when given acutely (see text for details and Table 3 ). Antidepressant drugs invariably increase aggression during chronic administration. Data on file unless otherwise indicated as follows; a [261] , b [264] , c [250] , d [275] , e [257] , f [259] , g [256] , h [263] , i [262] , j [254] .
in neurotransmitter function, as opposed to direct pharmacological effects, may underlie the common behavioural changes induced by chronic antidepressant treatment, including repeated ECS. Furthermore, the different rates of onset observed for different antidepressant drugs suggest that these adaptive mechanisms may be invoked at different rates depending on the antidepressant treatment used. It is generally accepted that while the delayed onset of clinical efficacy with TCA, SSRI and SNRI antidepressant drugs is difficult to equate with the acute pharmacological effects of these compounds, the inhibition of 5-HT and/or NA reuptake must play an important role in initiating such adaptive mechanisms. Evidence suggests that somatodendritic 5-HT 1A receptors located on the cell body of serotonergic neurons in the midbrain raphé nuclei have an inhibitory influence over the activity of central serotonergic neurons. Thus, acute inhibition of 5-HT reuptake results in a local increase in extracellular 5-HT that activates the somatodendritic 5-HT 1A autoreceptors which in turn reduces the firing rate of midbrain raphé neurons (e.g. see [272] ). Acute treatment Fig. (6) . Effect of chronic treatment via sc-implanted osmotic minipump with saline (open circles), venlafaxine (5.54 mg/kg/day/day; black triangles) or fluoxetine (0.34 mg/kg/day sc; black circles) on the aggressive behaviour of resident rats expressed during daily social encounters with unknown intruder conspecifics. Individual elements of aggressive behaviour were grouped according to motivational category (see Table 2 ) and expressed as a percentage of the total number of behavioural elements scored for each individual animal. The mean and SEM of the percentage values for 8 resident rats were then calculated. Saline-treated resident rats exhibited no change in the level of aggression throughout the study (repeated measures ANOVA; F(7, 49) = 0.84, P > 0.05). In contrast, venlafaxine-and fluoxetine-treated resident rats exhibited increased aggressive behaviour [Fs(7, 49) ≥ 9.25, P < 0.001 in both cases] from days 2 and 5 of treatment, respectively. Post hoc analysis (Bonferroni-Dunn (control) test); * P < 0.05, *** P < 0.001 c.f. saline-treated resident rats at each time point. Re-drawn from [275] . Fig. (7) . Effect of chronic treatment via sc-implanted osmotic minipump with water (open circles) or fluoxetine at 0.34 (black triangles), 1.02 (black circles) or 3.09 (black squares) mg/kg/day sc on the aggressive behaviour of resident rats expressed during daily social encounters with unknown intruder conspecifics. Individual elements of aggressive behaviour were grouped according to motivational category (see Table 2 ) and expressed as a percentage of the total number of behavioural elements scored for each individual animal. The mean and SEM of the percentage values for 8 resident rats were then calculated. The aggression exhibited by water-treated resident rats remained constant throughout the study. In contrast, the level of aggression exhibited by resident rats treated with fluoxetine, 1.02 and 3.09 mg/kg/day, was significantly increased from day 3 of treatment, while that of rats treated with 0.34 mg/kg/day fluoxetine was significantly increased from day 5. One-way ANOVA with repeated measures analysis revealed a significant TREATMENT * TIME interaction [F(21, 196 [273, 274] . To test this thesis a number of studies using the resident-intruder model were performed examining acute and chronic treatment with fluoxetine given alone and in combination with the selective 5-HT 1A receptor antagonist, WAY-100635. In these studies acute pretreatment with WAY-100635, 0.1 mg/kg sc, significantly potentiated the reduction in aggression induced by acute treatment with fluoxetine, 0.34 mg/kg sc (Fig. (8) ). Furthermore, in chronic treatment studies, resident rats treated with fluoxetine (0.34 mg/kg/day sc by osmotic minipump) alone exhibited increased aggression from day 5, while co-administration of fluoxetine with WAY-100635 (0.1 mg/kg/day) significantly increased the aggression exhibited by resident rats by day 2 (Fig. (9) ). As far as we are aware these were the first published studies to demonstrate the 'proof of concept' of the ability of a selective 5-HT 1A receptor antagonist (WAY-100635) to accelerate timedependent changes in a behavioural model induced by an antidepressant drug [275] . Fig. (9) . The effect of chronic treatment with WAY-100635, 0.1 mg/kg/day sc, on the time-course of increased aggressive behaviour induced by fluoxetine (0.34 mg/kg/day sc). Individual elements of aggressive behaviour were grouped according to motivational category (see Table 2 ) and expressed as a percentage of the total number of behavioural elements scored for each individual animal. The mean and SEM of the percentage values for 8 resident rats were then calculated. WAY-100635/fluoxetine-treated resident rats showed an increase in aggressive behaviour earlier during treatment than resident rats treated with saline/fluoxetine. 2-way ANOVA with repeated measures revealed significant interaction between TIME and both TREATMENT schedules [F(7, 196) = 2.28, P < 0.05].
Post hoc within-treatment analysis (repeated measures ANOVA followed by Bonferroni-Dunn (control) test as appropriate) revealed that the level of aggression exhibited by saline/water-treated control (open circles) and WAY-100635/water-treated (closed triangles) resident rats remained constant throughout the study. In contrast, resident rats treated with a combination of saline/fluoxetine (closed circles) or WAY-100635/fluoxetine (closed squares) exhibited increased aggressive behaviour from days 5 and 2 of treatment, respectively. Furthermore, between-treatment analysis (1-way ANOVA followed by Bonferroni-Dunn (all means) test at each time point as appropriate) revealed significant differences between the aggression level exhibited by WAY-100635/fluoxetine-and saline/ fluoxetine-treated resident rats on days 3 and 4 only. ** P < 0.01, *** P < 0.001 c.f. predose baseline level of aggression (Treatment Day 0) except between-treatment differences as indicated. Redrawn from [275] .
The resident-intruder paradigm, coupled with ethological analysis of behaviour, has therefore demonstrated that antidepressant drugs induce very specific changes in rodent agonistic behaviour that are dependent on the duration of drug treatment. Thus acute treatment with antidepressant drugs selectively reduces rodent aggression and such studies may be used to determine the relative potency between antidepressant drugs. In contrast, chronic treatment with these compounds, and also repeated ECS, markedly increases rodent aggression, indicative of increased assertive behaviour, thereby demonstrating diametrically opposite effects on behaviour compared to when these compounds are administered acutely. Furthermore, subjecting resident rats to social encounters on successive days allows the time-course of antidepressant changes in agonistic behaviour to be quantified. Together, these slight variations in the residentintruder paradigm allow the profile of preclinical antidepressant-like efficacy to be determined (including the potential utility of adjuvant treatment to existing antidepressant therapies) with respect to both drug dosage and rate of onset of appropriate changes in behaviour.
It was argued earlier that acute pharmacological challenge tests are useful to determine whether changes in neurotransmitter receptor-mediated function are associated with chronic antidepressant (including ECS) treatment. In these studies specific behaviours are induced in rats by acute treatment with selective ligands for a neurotransmitter receptor subtype. Comparison of the behavioural responses between control-and antidepressant-treated groups of subjects can then be used in an attempt to reveal differences from the expected behavioural response that may reflect changes in the function of the neurotransmitter receptormediated system under investigation. Such studies, however, are only of value if appropriate and valid chronic treatment schedules are used. A number of pharmacological challenge tests have been performed during chronic drug treatment schedules at various times appropriate to the onset of behavioural markers specific for antidepressant activity as identified by the resident-intruder paradigm (i.e. increased aggressive behaviour). In these studies [276] activity at 5-HT 2C receptors was measured in terms of hypolocomotion induced by mCPP. Chronic treatment with venlafaxine (5.54 mg/kg/day sc by osmotic minipump) reduced hypolocomotion after 2 days. In contrast treatment with fluoxetine and paroxetine (0.34 and 0.33 mg/kg/day sc, respectively, by osmotic minipump) did not produce a significant reduction in mCPP-induced hypolocomotion until day 9 (see Table 5 ).
In comparison, all three antidepressant drugs failed to modify 5-HT 2A receptor-mediated head shake behaviour induced by 1-(2, 5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) by day 7 of treatment. Furthermore, venlafaxine potentiated the 5-HT 1A receptor-mediated hypothermia induced by acute challenge with 8-OH-DPAT from day 5 of treatment. Thus chronic treatment with venlafaxine, administered at a daily dose which induces behavioural changes indicative of antidepressant activity, evokes a sequence of adaptive changes in the functional sensitivity of three serotonin receptor subtypes. Of these, reduced sensitivity of 5-HT 2C receptor-mediated hypolocomotion most closely follows the development of venlafaxine-induced increases in aggressive behaviour (see Fig. (10) ). The same studies [276] also showed that repeated ECS, administered on alternate days, abolished almost completely 5-HT 2C receptor-mediated function from day 3 (24h following a second shock), while, interestingly, 5-HT 2A receptor-mediated function was unaffected until 24h after a fourth shock (day 7) whereupon an increase in head shake response to DOI was observed. The similarity of the temporal sequence of adaptive changes in 5-HT 2A and 5-HT 2C receptor-mediated function induced by repeated ECS and chronic venlafaxine treatment clearly suggest that reduced 5-HT 2C receptor-mediated function is a prime candidate as a possible adaptive mechanism that underpins the increase in assertive behaviour induced by chronic antidepressant treatment. Such an explanation would also explain the increased aggressive behaviour observed following acute treatment with the 5-HT 2C receptor antagonist, mesulergine (see Table 3 ).
Social Hierarchy
The structure of social behaviour in a number of different orders of vertebrates is dependent on the agonistic behaviour appropriate to the antagonism between males. In the wild such behaviour either separates the males into territories (e.g. ferrets, mice) or arranges them in order of rank (e.g. apes). A This table compares the time for onset of antidepressant-induced increased rodent aggression (resident-intruder test) against changes observed in the behavioural or physiological responses to stimulation of 5-HT receptor subtypes. 5-HT1A receptor function was assessed by monitoring 8-OH-DPAT-induced hypothermia, 5-HT 2A receptor function was assessed by measuring DOI-induced head shake behaviour, and 5-HT2C receptor function was assessed by measuring mCPP-induced hypolocomotion (see text for further details). The time course for antidepressant-induced increased aggression most closely follows the reduction in 5-HT2C receptor-mediated function. References cited; a, ECS data from [254] ; b, drug aggression data from [275] ; c, 5-HT receptor function data from [276] . similar situation arises where male laboratory rats are housed in closed groups [233] . The respective rank position of rats in a closed group is related to the level of aggression exhibited by each group member when they are initially housed together. Thus higher aggressors achieve higher rank positions. Generally, the social hierarchy develops over a period of 2-3 weeks, but once established both the hierarchical structure and the level of aggressive behaviour remain essentially constant [236] . Thus, once the rank position of an individual rat is established it appears to be maintained through success in agonistic encounters with the cage partners [245] . However, group size is critical for the development of a stable social hierarchy in rats. Grant and Chance [236] showed that groups of 3-6 members demonstrated stable social hierarchies with distinct rank positions from about 3 weeks after grouping. Groups of 7 or more rats, however, showed social hierarchies where group members achieved different rank positions on successive observations, indicating that the rank positions were in a state of flux.
Various indicators of the dominance-subordinate relationships between members of closed social groups have been employed. Such measures fall into two distinct broad categories. First, the incidence of particular social behaviours or postures as used by Grant and Chance [236] , and, second, priority of access measures such as to food [244, 277] , drink [278, 279] or a sexual partner [280] . However, common problems associated with priority of access measures are that clear dominance hierarchies are not always apparent and that, where such hierarchies are observed, it is not uncommon for the presence of the 'dominant' rat to suppress the behaviour of the 'non-dominant' rats, thereby completely excluding the latter from the target food or drink. It is also possible, of course, that dominance hierarchies based on priority of access measures do not represent the true-dominance-subordinate relationships between group members, but merely reflect the respective abilities, or skills, of the group members to obtain the target [281] . Thus social hierarchies determined by the results of social and agonistic encounters between group members are arguably of greater heuristic value [282, 283] .
Observations of the social behaviour of grouped rats throughout their light-dark cycle indicate that intense levels of social and agonistic behaviour, involving all group members to an equal extent, routinely occur at the onset of the dark phase. Furthermore, such behaviour precedes any grooming or consummatory behaviour. This period of intense social behaviour may be analyzed using ethological techniques. In these studies [284] male Wistar rats were housed in triads (i.e. n=3). Each social interaction between the grouped rats during the initial 30 min of the dark-phase was carefully monitored and the 'winner' and 'loser' of each social interaction recorded. The 'loser' was identified as the rat which adopted the final posture(s) of either the FLIGHT SUBMIT or FLIGHT ESCAPE behavioural pathways (i.e. Submit posture, or Flag and Evade or Retreat, respectively) (See Table 2 ) in response to the aggressive posturing of a cage partner (which was therefore identified as the 'winner'). In some instances the social interaction was terminated by the loser exhibiting FLIGHT ESCAPE behaviour prior to any Approach by a more dominant cage partner. In these situations the result of the social encounter was recorded provided the winner and loser could be clearly identified. Interactions where no winner or loser could be unequivocally identified were ignored. The relative success level attained by each group member during social encounters was then calculated by expressing the total number of wins as a percentage of the total number of encounters in which that animal was involved. The highest success value indicates the dominant animal, the next highest the subdominant animal, and the lowest success value indicates the subordinate.
In all our studies, very little variation in the success scores were observed for the dominant, subdominant and subordinate rats, indicating that, first, the dominant-subordinate relationships between each pairing are essentially constant, and, second, that the social hierarchy for these groups of rats are also constant over the course of each experiment (Fig. (11) ). These observations indicate that rats housed in triads develop clear, definable and stable social hierarchy and the relative social position of each group member may be identified by assessing each individual's level of success Fig. (10) . Comparison between the time-courses of venlafaxine-induced increased aggression and reduced 5-HT 2C receptor-mediated function. Left y-axis indicates percentage reduction in locomotor activity induced by acute challenge of venlafaxine-treated rats with mCPP (2.5 mg/kg sc). Right y-axis indicates aggressive behaviour exhibited by resident rats (expressed as a percentage of total behavioural elements observed). Venlafaxine, 5.54 mg/kg/day sc administered by osmotic minipump. mCPP data re-drawn from [276] . Aggression data re-drawn from [275] .
during agonistic encounters with other group members. Furthermore, the intense levels of social and agonistic behaviour exhibited by grouped rats at the start of each dark phase of the light-dark cycle appear to indicate a fixed pattern of behaviour that enable the re-establishment of the hierarchical structure.
Early studies showed that administration of either clomipramine or mianserin for two weeks (at the same doses which increased the aggressive behaviour of resident rats in the resident-intruder paradigm; see Table 4 ) to the subdominant animal resulted in an increase in that subject's rank position at the expense of the level of dominance enjoyed by the dominant group member [284] . The increase in the social position of the antidepressant-treated subdominant rat is likely to be related to increased assertiveness expressed during social encounters. An attractive feature of this model is that daily assessment of social structure allows the timecourse of antidepressant-induced elevation of social position Fig. (11) . The effect of chronic treatment with clomipramine and venlafaxine on the social position of subdominant rats housed in triads. The vertical axis indicates the mean (±SEM) percentage success levels for dominant (triangles), subdominant (circles; closed circles indicate period of chronic treatment) and subordinate (squares) rank positions calculated after each behavioural recording of 6 groups of rats in each drug group. Days are indicated on the horizontal axis. Rank positions were assigned according to success scores calculated from the last recordings obtained prior to implantation of osmotic minipumps. In all experiments dominant and subordinate rats were implanted sc with osmotic minipumps containing saline. Subdominant rats were implanted with osmotic minipumps containing saline (top panel), clomipramine, 3.15 mg/kg/day (middle panel) or venlafaxine, 5.54 mg/kg/day (bottom panel). 2-way ANOVA with repeated measures analysis revealed a significant main effect of RANK position [F(2, 45) = 411.7, P < 0.001] but no effect of TREATMENT group or TIME indicating stable rank positions in each triad prior to treatment (days -2 to 0). In contrast, such statistical analysis revealed a significant interaction between TREATMENT * RANK * TIME both during (days D1 to D7) [F(24, 270) = 2.493, P < 0.001 with Hunyh-Feldt correction] and following (days Post 1 to Post 3) [F(98, 90) = 2.314, P < 0.05 with Hunyh-Feldt correction] treatment. Further analysis revealed a significant interaction between RANK position and TIME for both the clomipramine and venlafaxine, but not saline, groups during [both Fs(12, 90) ≥ 2.929, P ≤ 0.01 in both cases] and following [both Fs(4, 30) ≥ 4.373, P ≤ 0.01 in both cases] treatment. Post hoc analysis (BonferroniDunn (all means) test) revealed that clomipramine-and venlafaxine-treated subdominant rats increased their rank position by days 5 and 2 respectively. In the clomipramine-treated group the subdominant rats achieved parity of rank position with the dominant rats. In comparison, venlafaxine-treated rats achieved dominant status. Following the cessation of treatment the levels of success returned towards those observed prior to treatment. * P < 0.05, ** P < 0.01, *** P < 0.001 subdominant compared to dominant success scores. The success scores for salinetreated subdominant rats were significantly lower than the scores for the dominant rats throughout the experiment, while in all experiments subordinate success scores were significantly lower than either dominant or subdominant success scores (P < 0.001 in all cases, significance stars omitted for brevity). Mitchell & Redfern, data on file. to be determined. Recent studies have demonstrated that while subdominant rats chronically treated with saline (via osmotic minipump) maintain their level of success during social encounters with cage partners indicating constancy of social position, subdominant rats treated with clomipramine or venlafaxine, at doses which increase aggressive behaviour in the resident-intruder paradigm (see Table 4 ), exhibited increased social position from day 5 and 2, respectively ( Fig.  (11) ) at the expense of the level of dominance enjoyed by the dominant rats. Interestingly, venlafaxine-treated subdominant rats achieved full dominance over their cage partners while clomipramine-treated subdominant rats achieved parity of social position with their previously-dominant cage partners. Following the cessation of venlafaxine or clomipramine treatment the treated rats reverted back towards their original subdominant level. Importantly, the time course of the response to venlafaxine in these experiments corresponds closely to that in the resident-intruder paradigm (c.f. Fig.  (6) ). It can therefore be suggested that the adaptive changes in neurotransmitter receptor-mediated function that underpin the antidepressant-induced increases in assertive behaviour, which probably includes reduced sensitivity of neuronal mechanisms involving the 5-HT 2C receptor subtype, are also responsible for the ability of antidepressant drugs to increase the social position of subdominant rats in the social hierarchy test.
However, not all features of non-dominant animals are necessarily of relevance to depression, and the relationship between social dominance and social competition is potentially problematic. In group-housed rats competing for limited access to a high incentive reward, the performance of subordinate animals was improved by acute or chronic anxiolytic treatment [278, 285] , suggesting that the social competition test is relevant to anxiety rather than depression. Consistent with this view is the observation that chronic treatment with mCPP, a major metabolite of the antidepressant trazodone which itself possesses antidepressant activity (see Tables 3 and 4 ; [263] ), failed to increase the performance of subdominant rats in a social competition test [286] . However, the benzodiazepine anxiolytic diazepam, which improves performance in a social competition test, did not increase aggressive behaviour in dyadic encounters, after either acute or chronic administration, (Tables 3 and 4 ; [250] ). Further studies are necessary to confirm the ineffectiveness of anxiolytics in social dominance tests.
CONCLUSIONS
The diagnosis of depressive illness relies almost exclusively on observation of behaviour and inter-personal relations, and on reported feelings and beliefs of the patient. Consequently, modelling depressive illness is inherently difficult if not impossible (see [8] ) and even commonly used models of proven utility can rarely claim more than face and/or predictive validity (see section 2). In this review we have concentrated on one aspect of depressive illness and its treatment, namely the time lag between initiation of treatment and any measurable improvement in mood and behaviour. Clinical experience has shown that only rarely do antidepressants induce clinical improvement within the first two weeks of treatment. Assuming that the time lag for clinical efficacy is a real phenomenon, there is certainly some debate about whether this relates to the underlying disease state or about the mechanism(s) of action of currently available treatments. Traditionally, however, it has been a major consideration in the design of antidepressant drug screening tests that they respond to acute or subacute drug administration. A direct consequence of this approach is that such tests are incapable, by virtue of their design, of responding to the major current challenge of discovering new antidepressants that have a shorter onset of action. In contrast, animal models sensitive to chronic antidepressant treatment (including ECS) do have the capacity to detect a rapidly acting novel antidepressant treatment. It seems that most pharmaceutical companies now accept this view and have abandoned the high-throughput random screening approach in favour of the development of a small number of compounds specifically designed to meet predetermined pharmacological criteria. Consequently, behavioural screening methods now have their rightful place within the development phase of drug discovery.
The focus of this review has been to examine the time course of response to antidepressant treatments in a number of well-documented and well-established animal models of depressive illness. The ideal model should respond to chronic, but not acute, treatment with conventional antidepressants. The importance of this feature should not be underestimated since only when a model shows a gradual response that reflects a drug's gradual onset of action is it possible to detect a more rapid onset. Three models for which the clearest evidence for gradual onset of action has been obtained are CMS, the resident-intruder test and social hierarchy. Of these, two -the resident-intruder and social hierarchy paradigms -can legitimately claim face and predictive validity, in that the increase in aggressive behaviour during chronic treatment observed in these models can be seen as reflecting the increased assertiveness and drive in patients when the symptoms of endogenous depression begin to lift. Equally important is the observation that these behavioural effects are seen at clinically relevant doses that do not produce other, potentially confounding effects on behaviour. It is not, however, possible to claim construct validity for these models because at the molecular and neurochemical level the underlying causes of depressive illness remain unknown.
The clinical requirement for chronic treatment regimes has produced an extensive literature describing the effects of chronic antidepressant treatment in normal animals and reporting numerous changes in pre-and/or post-synaptic receptor function in a variety of neurotransmitter systems. These studies are pivotal in establishing mechanisms of antidepressant action. However, it is important to recognize that the specific mechanisms that underpin antidepressant efficacy may only be elucidated by using treatment schedules determined in animal models that induce behavioural markers specifically related to antidepressant action. Indeed, the inability to identify which of the many effects of antidepressants described in the literature are responsible for their therapeutic action is a fundamental limitation of this approach, and most likely reflects experimental naivety and the use of inappropriate treatment schedules. The development of animal models sensitive to chronic antidepressant drug treatment, in which a change of state is induced and maintained for a prolonged period of time, provides a powerful model for investigating these issues. It may be therefore, that examination of neurochemical changes accompanying the measured behavioural changes observed in the resident-intruder paradigm will, by extrapolation, throw some light on the underlying causes of clinical depression. The evidence from pharmacological-challenge studies accumulated thus far clearly suggests reduction in 5-HT 2C receptor-mediated function may be a key adaptive change in the serotonergic system associated with antidepressant efficacy. However, whether such a mechanism initiates antidepressant activity or occurs in response to other, as yet unidentified, changes remains to be seen. 
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